

From DEPARTMENT OF LABORATORY MEDICINE,  
DIVISIONS OF CLINICAL IMMUNOLOGY & TRANSFUSION MEDICINE  
AND HEMATOLOGY AND REGENERATIVE MEDICINE (HERM)  
Karolinska Institutet, Stockholm, Sweden

# **CROSSTALK OF HUMAN MESENCHYMAL STROMAL CELLS WITH THE CELLULAR COMPONENTS OF THE IMMUNE SYSTEM**

Regina Jitschin



**Karolinska  
Institutet**

Stockholm 2013

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet. Printed by Larserics Digital Print AB, Sundbyberg.

© Regina Jitschin, 2013

ISBN 978-91-7549-237-7

For my parents

## ABSTRACT

Using the potential of immune regulatory cell populations for cellular therapy constitutes an attractive tool to obliterate imbalances of immune responses in inflammatory disorders. In this context, adoptive transfer of mesenchymal stromal cells (MSCs) represents a relatively novel approach and its impact on the immune system has not been completely clarified. In this thesis we aimed to study the effects of MSCs on key immune cell types, which led us amongst others to investigate regulatory T-cells (T<sub>Regs</sub>), and myeloid cells.

We show that MSCs utilize the anti-oxidative, immune regulatory enzyme hemeoxygenase-1 (HO-1) for suppressing T-cell activation directly and for inducing T<sub>Regs</sub> (=indirect T-cell suppression). An inflammatory milieu generated by alloreactive T-cells led to the so-called ‘licensing’ of the MSCs boosting their regulatory capacity. Interestingly, HO-1 expression was substantially diminished during this process and its functions were taken over by other (up-regulated) molecules such as cyclooxygenase-2 thereby highlighting (functional) MSC plasticity.

Most MSC-based trials lack a systemic immune monitoring, which is key for interpreting the *in vivo* effects of MSCs. Performing a comprehensive flow cytometry-based immune screening in patients with acute graft-versus-host disease (aGVHD), treated with either third-party MSC or placebo infusions (in a double-blinded fashion), we were - most importantly - able to further corroborate the notion that MSCs function *in vivo* partly by promoting T<sub>Reg</sub>-subsets. Thereby, our data underscores the need for accompanying extensive immune analyses to better comprehend such “bench-to-bedside” approaches. Accordingly, we carried out thorough, laboratory investigations when we were the first to apply MSCs in a patient with treatment-refractory hemophagocytic lymphohistocytosis. Upon MSC infusion we could observe an increase of the immune modulating cytokine interleukin (IL)-10 in the serum and a preferential appearance of regulatory type 2 macrophages in the patients’ bone marrow. Altogether, this data confirmed previous findings from *in vitro* and animal model studies regarding the MSCs’ impact on myeloid cell populations. Driven by these observations we sought out to assess whether MSCs induce so-called myeloid derived suppressor cells (MDSCs) in aGVHD patients. Although we did not find an MSC-associated effect, we were the first to identify monocytic CD14<sup>+</sup>HLA-DR<sup>low/neg</sup> MDSCs accumulating after allogeneic hematopoietic transplantation. We characterized their suppressive function (*via* indoleamine-2,3-dioxygenase) and established a significant association with inflammatory cytokines and aGVHD. In fact, our data indicates that MDSCs are part of an immune regulating feedback mechanism that is activated during hyper-inflammations (such as in aGVHD).

Overall, our results indicate that immune regulatory populations play a decisive role in various inflammatory diseases and MSCs could boost their responses. Furthermore our work suggests that combining basic and translational research is pre-requisite for understanding the MSCs’ multifaceted interactions and for optimizing their clinical use.

## LIST OF PUBLICATIONS

- I. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cell.  
Mougiakakos D\*, **Jitschin R\***, Johansson CC, Okita R, Kiessling R, Le Blanc K. Blood. 2011 May 5;117(18):4826-35. doi: 10.1182/blood-2010-12-324038.
- II. Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells.  
Mougiakakos D\*, Machaczka M\*, **Jitschin R\***, Klimkowska M, Entesarian M, Bryceson YT, Henter JI, Sander B, Le Blanc K. Stem Cells Dev. 2012 Nov 20;21(17):3147-51. doi: 10.1089/scd.2012.0214.
- III. Immunosuppressive CD14+HLA-DR<sup>low</sup>/neg IDO<sup>+</sup> myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.  
Mougiakakos D\*, **Jitschin R\***, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K. Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215.
- IV. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation.  
**Jitschin R\***, Mougiakakos D\*, Von Bahr L, Völkl S, Moll G, Ringden O, Kiessling R, Linder S, Le Blanc K. Stem Cells. 2013 Apr 4. doi: 10.1002/stem.1386.

\* contributed equally



# TABLE OF CONTENTS

1	Introduction .....	1
2	Mesenchymal stromal cells .....	2
2.1	Discovery .....	2
2.2	Definition of MSCs .....	2
2.3	Immunogenicity .....	4
2.4	Crosstalk of MSCs with the immune system .....	5
2.5	MSCs as a therapeutic tool .....	8
2.6	Conclusion .....	12
3	Hematopoietic stem cell transplantation .....	13
3.1	History of hematopoietic stem cell transplantation .....	13
3.2	HLA-System .....	13
3.3	Immunological eradication of tumor cells .....	14
3.4	HSCT procedure .....	15
3.5	Complications after HSCT .....	17
3.6	Conclusion .....	22
4	Myeloid derived suppressor cells .....	23
4.1	MDSCs in health and disease .....	23
4.2	Phenotype .....	24
4.3	T-cell suppressive activity .....	26
4.4	Conclusion .....	31
5	Regulatory T-cells .....	32
5.1	Phenotypes .....	33
5.2	Suppressive mechanisms .....	34
5.3	Therapeutic potential for T <sub>Regs</sub> in the treatment of GVHD .....	37
5.4	Conclusion .....	37
6	Aims .....	39
7	Material and methods .....	40
7.1	Patients and donors .....	40
7.2	Methods .....	41
8	Results and Discussion .....	44
8.1	T <sub>Reg</sub> -induction by MSCs - a matter of plasticity (Paper I) .....	45
8.2	Myeloid cells as a target for MSC-based therapy (Paper II) .....	45
8.3	Regulatory cells as biomarkers in MSC treatment (Paper III & IV) .....	46
9	Conclusions .....	50
10	Acknowledgements .....	51
11	References .....	52

## LIST OF ABBREVIATIONS

AICD	Activation induced cell death
Allo	Allogeneic
APC	Antigen presenting cell
ARG1	Arginase 1
ATP	Adenosine triphosphate
cAMP	Cyclic adenosine monophosphate
CARD	caspase recruitment domain-containing protein
CMV	Cytomegalovirus
COX-2	Cyclooxygenase-2
CTL	Cytotoxic T-lymphocyte
CTLA4	Cytotoxic lymphocyte antigen 4
DC	Dendritic cell
DNA	Deoxyribonucleic acid
EBV	Epstein-Barr virus
FGL2	Fibrinogen like protein 2
FHL	Familial hemophagocytic lymphohistiocytosis
FOXP3	Forkhead box protein 3
G-CSF	Granulocyte colony stimulating factor
GVHD	Graft-versus-host disease
GVT	Graft-versus-tumor
HLA	Human leukocyte antigen
HLH	Hemophagocytic lymphohistiocytosis
HO-1	Hemoxygenase-1
HSC	Hematopoietic stem cell
HSCT	Hematopoietic stem cell transplantation
IDO	Indoleamin-2,3-dioxygenase
IFN- $\gamma$	Interferon- $\gamma$
Ig	Immunoglobulin
IL	Interleukin
iNOS	Inducible nitric oxide synthetase
ITG	Integrin
iT <sub>Regs</sub>	Induced regulatory T-cells
JAK	Janus kinase
L-NMMA	L-NG-monomethyl-Arginine acetate
LAG-3	Lymphocyte activation gene 3
LPS	Lipopolysaccharide
MDSCs	Myeloid derived suppressor cells
MS	Multiple sclerosis
MSC	Mesenchymal stromal cell
NADPH	Nicotinamide adenine dinucleotide phosphate
NK-cell	Natural killer cell
NO	Nitric oxide
NOD	Nucleotide-binding oligomerization domain-containing protein
Nor-NOHA	N $\omega$ -hydroxy-nor-Arginine
nT <sub>Regs</sub>	Naturally occurring regulatory T-cells



ONOO <sup>-</sup>	Peroxynitrite
PBMC	Peripheral blood mononuclear cell
PCR	Polymerase chain reaction
PD-1	Programmed cell death protein 1
PGE <sub>2</sub>	Prostaglandin E <sub>2</sub>
PMSCs	Peripheral mobilized stem cell
ROS	Reactive oxygen species
STAT	Signal transducer and activator of transcription
TBI	Total body irradiation
T <sub>Conv</sub> -cells	Conventional T-cells
TCR	T-cell receptor
TGF-β1	Transforming growth factor- β1
T <sub>H</sub>	T helper
TLR	Toll-like receptor
TNF	Tumor necrosis factor
TRAIL	Tumor necrosis factor related apoptosis inducing ligand
T <sub>Regs</sub>	Regulatory T-cells



# 1 INTRODUCTION

A functioning and balanced immune system is key to our existence. It efficiently protects us from invading pathogens, eliminates aberrant (malignant) cells and constantly evolves and adapts to new challenges. Cellular defects or dysfunctions in various diseases, but also iatrogenic conditions unbalance this tightly regulated system. This can render afflicted persons defenseless against pathogens and can drive the system out of balance leading to autoreactive, potentially life threatening processes. Besides traditional, drug-based approaches adoptive cellular therapy has emerged as an auspicious strategy. It aims to replace deficient or diseased parts of the immune system respectively to reestablish balance by introducing potent immune regulators into an unbalanced system. Cellular therapy's most successful representation is at the same its most holistic form: the allogeneic hematopoietic stem cell transplantation (alloHSCT).

AlloHSCT allows the replacement of an entire hematopoiesis and immune system and permits the cure for various hematological diseases. On the other hand, it exposes us to problems of unique complexity as we need to cope (a) with (transient) immunodeficiency, (b) a reconstituting immune system, and (c) potential rejection reactions (against the graft or the host). A plethora of innovative drugs and an emerging number of cell-based approaches have been introduced for the treatment of the complications following alloHSCT. As yet, studies based on adoptive T-cell transfer have dominated the field, such as virus-specific T-cells to boost host defense, donor lymphocyte infusion to ensure tumor eradication, and infusion of *ex vivo* expanded regulatory T-cells (T<sub>Regs</sub>) in order to attenuate the reactivity of the newly transplanted immune system against the host. In some settings natural killer (NK)-cell infusion was utilized for promoting anti-tumor immunity. However, cells other than lymphocytes are steadily gaining momentum, when it comes to restore immune homeostasis in rejection reactions and autoimmunity, with mesenchymal stromal cells (MSCs) being the most prominent representative and subject of this thesis.

Since their initial introduction ten years ago MSCs' safety and efficacy has been shown in several pre-clinical and clinical studies for the treatment of various inflammatory conditions (e.g. multiple sclerosis (MS), rheumatoid arthritis, and sepsis). However, it is still scarcely understood how exactly MSCs impact the immune system and how they exert their immune regulatory effects *in vivo*. We were in the privileged position to study the interaction of human MSCs with the innate and adaptive immune system at the 'bench' and then to try to validate our findings at 'the bedside' by analyzing unique sample collections from patients that had received MSC treatment.

The aim of all adoptive cell therapies is to exert very specifically the desired effect without systemic toxicity and without compromising the immune system in other ways. A profound understanding of the underlying immunologic mechanisms is *sine qua non* to improve cellular therapies and to allow further individualization. Much knowledge can be undeniably gained from *in vitro* and animal-models, however effective cellular therapy necessitates thorough evaluation of patient samples and clinical data for comprehending the *in vivo* processes in one of the most complex biologic systems – the human.


## 2 MESENCHYMAL STROMAL CELLS

### 2.1 DISCOVERY

Nowadays, multipotent mesenchymal stromal cells (MSCs) are widely known for their regenerative and immune regulatory properties. In the 60s of the last century Friedenstein et al. identified a small subpopulation of colony-forming unit fibroblasts (CFU-F) among bone marrow cells that are capable to form ectopic bone tissue [2, 3]. These cells could be easily distinguished from the rest of the bone marrow cells based on their plastic adherence, a spindle-shaped appearance, and a rapid expansion [3]. In humans, MSCs constitute about 0.001 to 0.01% of the bone marrow mononuclear cells isolated from Percoll gradient [4] and their number steadily decreases over lifetime [5]. MSCs can virtually be isolated from all mammalian connective tissues [4, 6] but to date bone marrow still remains the primary source while cord blood [7] and adipose tissue [8] gain more and more importance.

### 2.2 DEFINITION OF MSCs


As yet, no specific marker has been identified for MSCs. In 2006 the International Society of Cellular Therapy (ISCT) proposed a panel of so-called minimal criteria in terms of required function and surface antigens for classifying candidate cells as MSCs [9]. MSCs need to be plastic adherent under standard culture conditions and must display *in vitro* trilineage multipotency by differentiating into bone, fat, and cartilage. The markers CD73 (ecto-5'-nucleotidase), CD90 (Thy-1) and CD105 (endoglin, SH2) have to be expressed on over 95% of the cells. Additionally, MSCs lack myeloid markers (CD11b, CD14), hematopoietic progenitor and endothelial cell marker (CD34 (mucosialin)), the common leukocyte antigen (CD45), B-cell markers (CD19 or CD79a) and human leukocyte antigen (HLA)-DR [9].



**Figure 1: Phenotypical characterizations of MSCs.** MSCs are defined by the expression of CD73, CD90, CD105 and the absence of CD14, CD20, CD34 and CD45. This representative FACS analysis shows the characteristic expression profile of these markers (= red) in human bone marrow derived MSCs (grey= isotype control).

<b>Adhesion molecules</b>	
Immunoglobulin superfamily	ALCAM (CD166), ICAM-1 (CD54), ICAM-2 (CD102), ICAM-3 (CD50), NCAM (CD56), HCAM (CD44), VCAM (CD106)
Integrins (ITG)	ITG- $\alpha$ 1 (CD49a), ITG- $\alpha$ 2 (CD49b), ITG- $\alpha$ 3 (CD49c), ITG- $\alpha$ 5 (CD49e), ITG- $\alpha$ 6 (CD49f), ITG- $\alpha$ V (CD51), ITG- $\beta$ 1 (CD29), ITG- $\beta$ 3 (CD63), ITG- $\beta$ 5
Transmembrane superfamily	Tetraspanin (CD9)
<b>Toll-like receptors</b>	TLR1, TLR2, TLR4, TLR5, TLR6, TLR9
<b>Chemokine Receptors</b>	
C-C chemokine receptor (CCR)	CCR1, CCR2, CCR4, CCR6, CCR7, CCR8, CCR10
C-X-C chemokine receptor (CXCR)	CXCR1 CXCR2, CXCR4, CXCR5, CXCR6
CX3 chemokine receptor (CXCR1)	CX3CR1
<b>Growth factor receptors</b>	EGFR, FGFR, IGFR, PDGFR, TGF $\beta$ RI, TGF $\beta$ RII, NGFR
<b>Cytokine receptors</b>	
Interleukin (IL) receptors	IL-1R, IL-3R, IL-4R, IL-6R, IL-7R, Prolactin receptor (PRLR)
Prostaglandin (PG) E receptors	E prostanoid (P)1, EP2, EP3, EP4
Interferon (IFN)- $\gamma$ -, tumor necrosis factor (TNF) - receptors	IFN- $\gamma$ R, TNFRI (CD120a), TNFRII (CD120b)
<b>Ligands</b>	
Programmed death (PD) ligands	PD-L1 (CD274), PD-L2 (CD273)
	Notch ligand Jagged 1
<b>Signaling receptors</b>	
Wnt receptors	Fz2, Fz3, Fz4, Fz5, Fz6
Notch	Notch 1, 2, 3,
<b>Proteins</b>	STRO-1, MUC18 (CD146)

**Table 1: Receptors and molecules that have been identified to be expressed on MSCs.**



**Figure 2: Differentiation capability of stem cells.**

Based on their assumed capacity for self-renewal, the term mesenchymal stem cell was introduced in the 1980s [5] and became widely popular in the 1990s [10]. Stem cells per definition differentiate under the appropriate conditions into various cell types and replenish lifelong tissues with new cells. According to their plasticity and differentiation versatility, they are classified as totipotent, pluripotent and multipotent stem cells (Figure 2).

MSCs retain for up to 40 cell divisions their trilineage multipotency [11]. However, not all individual MSCs exhibit the same level of multipotency. MSCs seem to rather comprise a mixture of cells being at different maturation levels, of which many are solely mono- or bipotent [12]. Furthermore, excessive expansion of MSCs

*in vitro* has been associated with a loss of differentiation capability, telomere shortening along with genetic or epigenetic modifications, resulting in senescence and apoptosis [13-15]. It is therefore still an ongoing debate whether MSCs truly represent stem cells. Currently, the term ‘multipotent mesenchymal stromal cells’ more and more replaces the potentially equivocal term ‘multipotent mesenchymal stem cells’ [11].

## 2.3 IMMUNOGENICITY

MSCs were considered an attractive tool for adoptive cell therapy early on. This is partially owed to a key immunological feature: their so-called immune-privilege, which means that they do not elicit a specific immune response when infused in HLA-non-identical hosts.

HLA-Class I and II are the two major classes of HLA-molecules on cell surfaces that present peptides of processed antigens to immune cells. HLA-Class I molecules present peptides of cytosolic antigens that have been synthesized within the cell. If these self-antigens are a flawless presentation of ‘self’, they inhibit NK-cell mediated toxicity. However, if the presented self-antigens exhibit alterations e.g. due to viral infections, tumors or if HLA-Class I is down-regulated in malignant diseases, cytotoxic T-cells (CTLs) along with NK-cells are activated and ideally eliminate the aberrant cell. HLA-class II molecules are expressed at high densities on phagocytizing cells and antigen presenting cells (APCs). Alloantigens are taken up, processed, and presented to immune cells thereby initiating their activation leading to potent antigen-specific immune responses.

Un-stimulated MSCs are positive for HLA-Class I molecules and can therefore inhibit NK-cell mediated lysis [16]. Furthermore, un-stimulated MSCs are negative for HLA-Class II molecules [17]. This remarkable characteristic allows cell-transfer across HLA-barriers and makes them a *bona fide* tool for an “off the shelf” cell therapy [18, 19].

## 2.4 CROSSTALK OF MSCs WITH THE IMMUNE SYSTEM

MSCs exhibit numerous immune regulatory mechanisms interfering with the innate and the adaptive immune system (Table 2). To describe all the different populations and immune compartments in detail is beyond the scope of this introduction. Therefore, this chapter focuses mainly on the aspects that have been addressed within this thesis.

The majority of the observed immune regulatory effects can be attributed to a plethora of enzymes and secreted immune modulatory factors encompassing cytokines, chemokines and interleukins (Figure 3). Most data on the interaction of MSCs with immune cells originate from preclinical studies, which did not always produce consistent results. Over time it became apparent that these mostly *in vitro* observed effects depend on the origin of MSCs (tissue as well as species), condition and duration of culture and the activation status of responder cells as well as MSCs.

<b>Innate immune system</b>	[11]
Complement	[20, 21]
TLR-signaling	[11]
Macrophages	[22]
Dendritic cells	[23, 24]
Neutrophils	[25]
Mast cells	[26]
NK-cells	[27, 28]
<b>Adaptive immune system</b>	
T-cells	[29]
T <sub>H</sub> 1-T <sub>H</sub> 2 Balance	[30]
Induction of T <sub>Regs</sub>	[31]
B-cells	[32]

**Table 2: Overview over the identified interactions of MSCs with the different parts of the innate and adaptive immune system.**

Recent data suggests that an inflammatory environment, in particular abundance of cytokines such as interferon (IFN)- $\gamma$ , tumor necrosis factor (TNF)- $\alpha$ , Interleukin (IL)-1 $\alpha$  and IL-1 $\beta$ , activates MSCs [33]. This process is called “licensing” [34] and results in an increased immune suppressive potency due to an elevated expression of immune regulatory molecules (Table 3) such as indoleamine-2,3-dioxygenase (IDO) or cyclooxygenase-2 (COX-2) [35, 36]. In fact, it can be speculated that MSC-“licensing” is part of physiological negative-feedback mechanisms that are activated for preventing the exacerbation of inflammatory responses. Actually, there are even efforts to integrate the MSCs’ responsiveness to *in vitro* “licensing” (with IFN- $\gamma$  and TNF- $\alpha$ ) in the evaluation process for screening the most potent MSCs to be used in clinical approaches [33].

<b>Immune modulatory molecules</b>	B7-H1 / PD-L1 / CD200 / CD274
<b>Cytokine / chemokine receptors</b>	CD119 / IFN- $\gamma$ receptor, CXCR3, 4, 5, CCR7
<b>Adhesion molecules</b>	CD54, CD106
<b>DNAM ligands</b>	CD112, CD115
<b>NKG2D ligands</b>	Macrophage inflammatory complex A/B, UL binding protein 1, 2, 3
<b>Notch receptors</b>	Jagged-1
<b>TLR</b>	TLR-3, TLR-4
<b>Cytokines</b>	IDO, COX-2

**Table 3: Upregulated molecules and cytokines upon inflammatory licensing [33].**

Lymphoid cells were the first to be identified as preferential targets of MSC-mediated effects. Soluble factors (e.g. IL-10 and prostaglandin (PG) E<sub>2</sub> [37, 38]), as well as cell-to-cell contact-dependent mechanisms (interaction of programmed death (PD)-1 with its respective ligands (PD-L1, PD-L2) [39]) are both involved in T-cell inhibition. MSCs suppress in a dose-dependent fashion the proliferation, IFN- $\gamma$  production, and cytotoxicity of activated CD4<sup>+</sup> and CD8<sup>+</sup> T-cells [24, 40, 41].


Induction of T-cell apoptosis as mean of MSC-mediated T-cell suppression is still under debate [42, 43]. However, activation induced cell death (AICD) of T-cells is shown to be decreased as a consequence of the attenuated T-cell activation in the presence of MSCs. Furthermore, MSCs indirectly diminish T-cell responses by preventing maturation and thereby antigen priming function of the main APCs: the dendritic cells (DCs) [44-47].

The different types of differentiated T-cells regulate the immune response. Increased frequencies of IL-17-producing T-cells have been associated with various inflammatory diseases. MSCs were shown to prevent the differentiation of naïve CD4<sup>+</sup> T-cells into pro-inflammatory Th17-cells [48, 49]. Furthermore, by inducing T<sub>Regs</sub>, MSCs amplify their immune regulatory capacity. They directly induce T<sub>Regs</sub> by expressing immune modulatory enzymes or molecules such as HLA-G [50] and hemeoxygenase-1 (HO-1) [31]. Furthermore, by e.g. secretion of IL-10 and PGE<sub>2</sub>, MSCs skew other cell types (e.g. monocytes and DCs) towards regulatory phenotypes capable of T<sub>Reg</sub> induction [24, 47]. Recently, we confirmed the positive effect of MSCs on T<sub>Regs</sub> induction *ex vivo* in patients receiving a third-party MSC infusion [51].

Similar to the inhibitory effect on T-cells, co-culturing MSCs with (CpG oligonucleotide 2006, anti-immunoglobulin (Ig) antibodies, IL-2, IL-4, IL-10) stimulated B-cells leads to an inhibition of B-cell proliferation, impaired Ig-secretion, and lack of CXCL-12 driven B-cell chemotaxis *in vitro* [32]. Furthermore, MSCs impair the maturation of B-cells into Ig-producing plasma cells [52]. Candidate molecules for mediating these B-cell suppressive effects are tumor growth factor (TGF)- $\beta$ 1, hepatocyte growth factor (HGF), PGE<sub>2</sub> and IDO [32]. These observations have recently been challenged by studies showing that MSCs actually support survival, proliferation and differentiation of B-cells [53, 54]. The effect on B-cells is a typical example of how the type of effect elicited by MSCs varies depending on the activation status of responder cells (in this case B-cells) and MSCs: MSCs present in a mixed lymphocyte



culture can inhibit IgG, IgA and IgM production, an effect that is abrogated, if B-cells are stimulated with CD40L [55]. Furthermore, as Rasmusson et al. demonstrated, the grade of MSC activation is critical. There seems to be a direct correlation of the potency of the stimuli present in the co-culture and the MSC mediated effect. Under low stimulation with lipopolysaccharide (LPS) or viral antigens MSCs increase Ig-production by B-cells, but have an Ig-reducing function in the presence of high levels of the aforementioned stimuli [54].



**Figure 3: Impact of MSC-derived soluble factors on T-cells and myeloid cells.** MSCs express and secrete a plethora of molecules that have direct inhibitory effects on myeloid and T-cells. Furthermore, MSCs induce an immune regulatory phenotype in both, lymphoid and myeloid cells. Inflammatory cytokines such as IFN- $\gamma$  and TNF- $\alpha$  elicit an inflammatory licensing of MSCs, which leads to the up-regulation of *inter alia* IDO and COX-2 thereby further potentiating their immune regulatory potency.

Two key cell populations for anti-viral and anti-tumor immune defense are the CD8<sup>+</sup> CTLs and NK-cells. Since MSCs express only low levels of HLA-Class I molecules ("missing self") and several NK-cell activating ligands (ligands for NKG2D e.g. ULBPs, MICA and ligands for DNAM-1 PVR, Nectin-2), they should be targeted by NK-cells [27]. Whether MSCs are lysed or not by NK-cells depends on (1) the NK-cell pre-activation status [16, 28, 56, 57] and (2) the tissue origin of MSCs [58], which additionally also determines the elicited death pathways (TRAIL by fetal MSCs or FasL by adult MSCs) [59]. Then again, it has been shown that MSCs lead to the down-regulation of activating NK-receptors (NKp30, NKp44, NKG2D) [28] and impact negatively by COX-2 [57] and IDO [60] the IFN- $\gamma$  production [24], proliferation [28] and cytotoxicity of NK-cells.

Peptides of cytosolic processed antigen of virus-infected cells and tumor cells presented by HLA-Class I lead to the activation and proliferation of CD8<sup>+</sup> CTLs. CD8<sup>+</sup> CTLs

play a pivotal role for the elimination of these diseased cells by releasing e.g. cytotoxic granules and pro-apoptotic surface receptors [61, 62]. Despite HLA-Class I expression, allogeneic MSCs exhibit a low susceptibility to CTL-mediated lysis and do not lead to CTL-activation, even if pulsed with synthetic peptide [61].

The inhibiting role of MSCs seems to be limited to the initial stimulation phase of CTLs, where they inhibit formation of antigen-specific CTLs and target cell lysis [63, 64]. MSCs do not have an effect on the cytotoxic phase [47, 61, 64] and interfere only to a small extent with the lysis mediated by viral-antigen-specific memory CTL *in vitro* and *in vivo* [47, 63].

Despite this *in vitro* evidence, if MSCs impair anti-viral responses *in vivo* has not been completely resolved. In patients that were treated with MSCs for steroid refractory graft-versus-host disease (GVHD) a higher incidence of cytomegalovirus (CMV) infections in GVHD affected organs was observed [65]. However, compared to a historic control MSC treated GVHD patients did not experience a higher rate of viral infections and exhibited a sufficient anti-viral response [66].

MSCs have a (1) chemotactic as well as an (2) immune regulatory effect on myeloid cells. MSCs attract macrophages and monocytes in case of tissue damage and/or mobilize them from the bone marrow by secreting monocyte chemotactic protein 1 (MCP-1) in response to generalized inflammatory reactions as seen during sepsis [67]. This potentially serves two effects: first, macrophages and monocytes boost the clearance of invading organisms and cell debris, which is a prerequisite for wound healing [68, 69]. Next, MSCs can regulate inflammation by shifting the type of cytokines produced by myeloid cells. Induction of IL-10 by e.g. IDO [70] or PGE<sub>2</sub> [22] can lead, as convincingly demonstrated in a murine sepsis model, to a significantly better control of inflammation and finally survival [22]. In a recent study it has been shown that MSCs induce a myeloid derived suppressor cell (MDSC)-like phenotype in monocyte-derived DCs. These cells were immune suppressive and capable of skewing conventional T-cells towards a tolerogenic immunophenotype [71].

**Monocytes** can be polarized by a the surrounding environment in an acute inflammatory phenotype (M1), which plays an important role in host defense for example by phagocytosis of bacteria, and an alternative type of monocytes (M2), which is immune-regulatory and important for maintaining immune tolerance as well as tissue repair.

Taken together, MSCs exert a multifaceted immune regulatory response in various cells of the immune system. Overall, they seem to induce a more tolerogenic milieu, which is even more potentiated in an inflammatory environment. MSCs elicit inhibiting effects, directly by e.g. impairing inflammatory immune responses or indirectly by inducing immune regulatory populations such as T<sub>Regs</sub> and alternative type monocytes.

## 2.5 MSCs AS A THERAPEUTIC TOOL

As discussed above MSCs exhibit a potent capacity for immune regulation and tissue regeneration. MSCs can be isolated with relative ease from healthy donors and quickly multiplied *in vitro*. Together with their low immunogenicity, they can be transplanted across HLA-barriers and can be used as a third-party off-the-shelf product to treat patients. This section will briefly describe the different current applications of MSCs.

### 2.5.1.1 Regenerative medicine

Since their differentiation capability into various tissues was the first well-defined feature of MSCs, their clinical application was initially focused on tissue replacement and regeneration. MSCs secrete many factors that promote wound healing and restoration of physical barriers [72]. Furthermore, in murine models, it was demonstrated that MSCs quickly home to sites of tissue injury [73, 74]. Infusion of MSCs was for example successfully used to substitute defective bone tissue in osteogenesis imperfecta patients [75]. Osteogenesis imperfecta is a congenital bone disorder characterized by the defective production of Type I collagen. This defect leads amongst others to frequent bone fractures resulting in bone deformities. In a seminal study, fetal MSCs were transplanted *in utero* in a human female fetus with severe osteogenesis imperfecta, manifesting already with multiple intrauterine bone fractures. The engraftment of the transplanted MSCs was successful despite existing immune competence of the host [76].

A further scope of the regenerative intended application of MSCs constitutes a very common disease of the western world: myocardial infarction. Myocardial infarction is accompanied by scarring of the affected heart tissue leading to diminished contractility of the heart muscle and hence a less effective pumping function. In pig models of myocardial infarction, it was shown that MSCs infused in the affected coronary artery had a beneficial effect on the recovery of heart function [77]. MSCs release a broad array of trophic and immune regulatory molecules (thereby limiting inflammation of the damaged tissue) but may also stimulate the endogenous cardiac stem cells recruitment and differentiation [78, 79].

Recently, the research in tissue engineering has focused on integrating bioartificial scaffolds to potentiate tissue regeneration. Maccarini et al. demonstrated the great potential this approach holds by using stem cells grown on a scaffold to replace a tracheobronchial airway tube in a patient after its own trachea had been removed due to tumor resection [80].

### 2.5.1.2 Immunomodulation

The discovery of the immune regulating functions of MSCs heralded their era as a potential cellular therapy for (hyper-) inflammatory diseases. In fact, *in vitro* evidence suggests that MSCs migrate towards inflammatory cytokines and in response to complement namely the component 1 subcomponent q (C1q) [81], C3a and C5a [20]. This feature might indicate their tropism towards the site of damage and inflammation. This is very useful in terms of their migration towards the preferential areas of action upon infusion.

MSCs are currently evaluated for the treatment of several autoimmune disorders [11], such as autoimmune arthritis [82] and autoreaction-driven

#### **Hemophagocytic lymphohistiocytosis (HLH)**

is a rare autoimmune disease. Two forms exist: the primary, familial HLH, which is based on genetic mutations and the secondary, reactive form, which is triggered by viruses, bacteria and parasites.

HLH patients present with hepatosplenomegaly and fever, hyperactivation of T-cells and macrophages, which results in a cytokine storm. This leads to the hyperactivation of macrophages and increased production of TNF- $\alpha$ , IL-6, ferritin and ultimately the phagocytosis of leukocytes accompanied by the typical cytopenia.

neurological diseases amongst others amyotrophic lateral sclerosis and MS. In animal models of MS and amyotrophic lateral sclerosis the beneficial effect of MSCs has been demonstrated [43, 83] and currently, adoptive transfer of MSCs is evaluated in clinical trials [84]. Furthermore, MSCs have been anecdotally used as rescue therapies or for “bridging” a desolate inflammatory situation (until allogeneic hematopoietic stem cell transplantation (alloHSCT) could be performed), in which standard treatment was ineffective e.g. in rare autoimmune diseases such as HLH [85] and autoimmune enteropathy [86].

#### 2.5.1.2.1 MSCs in hematopoietic stem cell transplantation

In the bone marrow niche, stromal cells (including MSCs) support hematopoiesis. MSC function can be impaired after chemotherapy [87] leading to a prolonged reconstitution harboring an increased risk for infections. Therefore the hope for an accompanying infusion of *in vitro* expanded human MSCs together with hematopoietic stem cells (HSCs) was to achieve a faster reconstitution. This is especially of interest for patients that receive HSCs from a haploidentical donor or cord blood, which are regularly associated with delayed engraftment (see section 3 of this thesis). Indeed, the first studies in transplanted breast cancer patients showed an improved reconstitution after alloHSCT if MSCs were co-infused [88]. Equally important, no adverse effects were registered [89]. Also in haploidentically-transplanted patients, infusion of MSCs led to quicker lymphocyte recovery [90]. In pediatric patients a co-infusion of *in vitro* expanded MSCs failed to prevent graft rejection, however MSCs appeared to prevent another life threatening complication after alloHSCT: the development of acute GVHD (aGVHD) [91]. Severe aGVHD is one reason for the high morbidity and mortality after HSCT (see section 3.5.3). In short, aGVHD is characterized by hyperactivated T-cells of the graft, which react against healthy tissue of the host. Steroid treatment constitutes the first-line therapy to which about 50-60% of all patients respond [92]. The response to treatment correlates with severity of disease and patients with milder GVHD show a better response rate (> 60%), than severe GVHD (Grade IV 33%) [92]. However, in the event of steroid unresponsiveness, aGVHD can become treatment-resistant and is associated with high morbidity and mortality (up to 90%) [93].

**Haploidentical** means that the donor and recipient are genetically identical for half of the HLA molecules

Cellular therapy has emerged as a promising tool for the complications (including GVHD) that occur during the post-transplant period. One of them is the adoptive therapy of MSCs. Le Blanc et al. were the first to administer cryopreserved, third-party MSCs for severe aGVHD with gut and liver involvement in a pediatric patient that did not respond to conventional treatment. The infusion of haploidentical MSCs from the patients’ mother led to a remarkable clinical improvement and durable complete remission. Importantly, no toxic side effects were observed [94].

The adoptive transfer of MSCs still remains a relatively novel experimental approach to treat aGVHD. Despite the vast knowledge gained during the last decade many questions remain unresolved and observations are not always coherent. In contrast to the unequivocal beneficial effects demonstrated in clinical phase I and II trials in aGVHD carried out at European academic facilities, a commercial, large phase III study by Osiris (Therapeutics Inc Columbia, MD, USA) failed to reach the primary end-point of the study. It is important to stress out that in this Osiris-led study MSCs of

only few donors were heavily expanded, which is a major contrast to the studies carried out at academic houses, where MSCs from one donor and at low passages were transferred into one patient [95]. Low passages seem to be a prerequisite for a more effective MSC function [65]. In the future, it will be of great importance to develop, integrate, and harmonize protocols, which will allow us the identification of the most potent, e.g. in terms of immune regulation, MSCs for clinical application. Consensus regarding MSC selection criteria, culturing protocols and expansion rate would furthermore result in a higher comparability among studies.

### 2.5.2 Safety

Every novel treatment has to be critically reviewed in regards of any occurring adverse events and in comparison to established standard treatment. MSCs exhibit low toxicity and no adverse side effects have been reported during or right after MSC administration irrespective of treatment indication [89, 94, 96, 97].

Since MSCs are a relatively new cellular therapy, long-term risks are still very poorly evaluated in large cohorts. No spontaneous formation of ectopic bone or cartilage formation was shown for the infusion of autologous human MSCs together with autologous HSCs [88, 89] and even more importantly no ectopic tumor formation was observed for MSCs [98].

In particular, aside from an elevated risk of infections due to impaired immune responses, any immune suppressive treatment might lead to increased relapse rates in patients that underwent HSCT to treat a malignant disease. As described above MSCs have been shown to impact CD8<sup>+</sup> CTLs [61] and NK-cells [27, 28]. Both are critical for the prevention of (malignant) diseases and virus-clearance, but on the other hand activated CTLs also drive GVHD [61]. *In vitro* evidence shows that although MSCs suppress the primary alloantigen-induced proliferation and IFN- $\gamma$  production by human peripheral T-cells, they seem to be able to exert a selective T-cell control. They do not impair expansion of CMV and Epstein-Barr virus (EBV) pentamer-specific T-cells nor the proliferation or cytolytic-killing in established CMV- and EBV-specific CTLs [63].

### 2.5.3 Engraftment

One yet not completely resolved puzzle is the way of redistribution of MSCs upon infusion respectively engraftment. In animal models a quick distribution to the lungs was shown immediately after infusion [99]. In patients with cirrhosis that were infused with <sup>111</sup>In-oxine labeled MSCs, cells accumulated initially in the lungs, and then redistributed to spleen and liver, where they could be detected up to 10 days [100]. In case of non-human primates, MSCs were detected in gastrointestinal tissue, lung, liver, kidney, thymus and skin after several months at a range of  $1 \times 10^3$  to  $2.7 \times 10^4$  cell equivalents per microgram of DNA [101]. If tissue was injured prior to infusion for example due to irradiation, even higher rates (up to 10%) were to be observed [102]. In HSCT-patients, MSC long-term engraftment was extremely low and scarce as assessed in autopsies [103-105]. Overall, these observations indicate that MSCs do not integrate into host tissue thereby exerting long-term activity. MSCs appear to mediate their effects in a rather

**Engraftment** is the successful integration of transplanted cells in the recipient bone marrow niche. In stem cell transplantation this refers to the time point when the transplanted

“hit-and-run” fashion. Upon infusion MSCs might represent “only” the trigger for initiating a cascade of immunological events that lead to a more tolerogenic immune profile (=tolerogenic immune memory) and thereby indirectly shift (or even restore) the balance of immunological processes.

## **2.6 CONCLUSION**

Compared to other cellular therapies like HSCT discussed in the next chapter, the adoptive transfer of MSCs for inflammatory diseases is a very novel approach. Despite the repetitively documented clinical responses, mechanisms by which MSCs exert *in vivo* their immune regulatory effect have not been fully deciphered not allowing us to predict which patient would benefit the most from such treatment or to monitor treatment efficacy at a cellular level. In order to develop more individualized protocols and to achieve the most effective MSC therapy possible, a profound understanding is therefore indispensable. Due to the lack of convincing preclinical models (as rodent MSCs are vastly different from human MSCs), basic research on MSCs has overall occurred *in vitro*, and was furthermore confused by the big inter-study variances. For the future, synchronizing manufacturing and culturing protocols would immensely help to transfer the knowledge gained *in vitro* to the clinical setting. We are of the opinion that it represents a key step for ensuring that the beneficial effects of MSCs stay in the limelight and are not overshadowed by potential inconsistent results.

### 3 HEMATOPOIETIC STEM CELL TRANSPLANTATION

Hematopoietic stem cell transplantation (HSCT) is the most successful and routinely used form of cellular immunotherapy [106]. It allows replacing a failing or diseased hematopoiesis and immune system with a new, healthy one. Furthermore, it represents the only curative option for many hematological malignancies [107] with patients suffering from leukemia and lymphoma accounting for the largest patient cohort.

#### 3.1 HISTORY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

HSCT was initially developed for two reasons: (1) to treat patients with immune deficiencies and inherited anemia and (2) as a rescue therapy after myeloablative cancer therapy. In 1951 the seminal study by Lorenz et al.

##### **Myeloablation**

describes the situation in which the bone marrow is completely depleted of bone marrow cells by high doses of chemotherapy or irradiation. This leads to a complete failure of hematopoiesis and is therefore lethal.

demonstrated for the first time in lethally irradiated mice that the transplantation of syngeneic as well as autologous bone marrow allows reconstitution of a sufficient hematopoiesis that ensures survival [108]. This reconstitution can be attributed to a small number of HSCs in the bone marrow that is characterized by the expression of the cell surface protein CD34, which seems to function as a cell-to-cell adhesion factor. Furthermore, CD34 might also impact cell proliferation and maturation but its function has not yet been completely understood [109]. These CD34<sup>+</sup>

HSCs regenerate primitive progenitors, which reproduce less-differentiated precursors and finally develop into mature blood cells. Since peripheral blood cells exhibit a limited life span, a constant replenishment of the peripheral blood pool is important to maintain sufficient blood cell numbers throughout the body.

The first HSCT in humans was performed in the late 1950ies in a patient with end-stage leukemia [110]. Even though hematological recovery was achieved in some transplanted patients, the outcome of the early transplantations remained poor. A study investigating the survival of patients that received transplants between 1958 and 1968 showed that in 1970 only three out of 203 patients were still alive [111]. This can partly be attributed to the advanced stages of disease of the treated patients, but also due to the limited understanding of the immunological processes initiated by the transplantation of a whole immune system.

#### 3.2 HLA-SYSTEM

The discovery of the importance of the HLA-system by J. J. van Rood and J. Dausset in the 1960s was one of the most decisive developments towards an individualized stem cell therapy and made transplantation of third-party stem cells feasible. HLA-molecules are expressed on the surface of cells and present peptides recognized by immune cells allowing the distinction from self- and non-self-antigens [112, 113]. This plays an arbitrate role for the whole function of the immune system in every human being, but also explains many of the immunological adversities faced upon alloHSCT.

HLA-genes consist of three main classes that are structurally and functionally different. All nucleated cells express HLA-Class I genes however at varying levels. HLA-Class I

molecules present peptides of processed cytosolic antigen and are essential for regulating the NK-cell mediated cytotoxicity and for triggering CD8<sup>+</sup> CTLs. Twenty different genes exist, the most important ones are HLA-A, -B, and C.

HLA-Class II genes present endo- and phagocytized extracellular antigens and are normally expressed by specialized immune cells as e.g. professional APCs, B-cells, activated T-cells, and thymic epithelial cells. The class II genes encode for the alpha and beta polypeptide chains of the class II molecules. The most significant ones are HLA-DR, HLA-DQ, and HLA-DP. So far, HLA-Class III plays a minor role in transplantation and is involved in immunity by expression complement factors and cytokines.

Since each person has a specific combination for his or her histocompatibility complexes, it is essential to thoroughly evaluate the HLA-region for matching recipients with adequate donors. Taken together, the rate of rejection, occurrence and severity of GVHD as well as the grade of delay in immune reconstitution is proportional to the degree of mismatch between donor and recipient [114, 115].

### 3.3 IMMUNOLOGICAL ERADICATION OF TUMOR CELLS

Although patients undergoing alloHSCT are overall well pretreated and at best disease free or exhibit minimal residual disease, it is always possible that some tumor cells survive the therapy leading to the relapse of disease. This is especially true for stem cell diseases such as leukemia. Cancer stem cells are quiescent, metabolically inactive cells that remain in G<sub>0</sub>-state and do not proliferate [116]. As most chemotherapeutic agents act almost exclusively on proliferating cells, some malignant stem cells might

successfully evade even lethal doses of total body irradiation (TBI) and chemotherapy.

#### **Cancer immunosurveillance:**

F.M. Burnet and L. Thomas postulated the hypothesis that cancer cells are targeted and recognized by the immune system namely lymphocytes.

Every healthy, well-functioning immune system recognizes and targets malignant cells to a certain degree (concept of cancer immunosurveillance) [117, 118]; however soon after alloHSCT was introduced, it became apparent that the transplantation of a third

party donor-derived graft results in lower relapse rates (35 percent) [119] than the transplantation of a syngeneic or autologous graft (40 to 75 percent) [120]. In subsequent studies, it was elucidated that the potential to target and eliminate residual tumor cells (graft-versus-tumor (GVT) effect) was mediated by the alloreactivity of the allogeneic graft against the host. An allogeneic graft consequently does not only recognize cancer cells as malignant (based on the expression of tumor antigens), but also as foreign and therefore kills them even more efficiently [121]. This effect is predominantly conveyed through host-reactive co-transplanted donor-derived CTLs that react against recipient HLA-complexes. [122]. Increasing evidence suggests that in certain haploidentical donor-recipient constellations observed GVT effect can also be mediated by NK-cells [123].

In a seminal study, H.J. Kolb demonstrated that the infusion of additional donor derived lymphocytes so-called DLI in the post-transplant period can potentiate respectively boost the GVT effect [124]. This has laid the foundation to an effective immunological targeting of cancer cells by the transplanted immune system. It revolutionized cancer



therapy respectively changed the perception of conditioning therapy allowing the introduction of a non-myeloablative conditioning therapy (see section 3.4.2).

### 3.4 HSCT PROCEDURE

In principle a successful HSCT follows three consecutive phases (1) a suitable graft has to be selected first. Depending on underlying disease, the transplant can be the (A) patient's own stem cells (autologous), (B) stem cells from genetically identical siblings (syngeneic) or (C) third-party derived stem cells (allogeneic). (2) Before receiving the transplant, each patient has to undergo a therapy that creates the right conditions ('conditioning therapy') in the host to receive the transplant. (3) Transplantation is followed by a post-transplant period characterized by immunodeficiency until the new immune system reconstitutes resulting in a healthy, functioning immune system.

#### 3.4.1 Graft and sources of stem cells

The primary graft source for the first HSCTs was bone marrow. Bone marrow cells are collected under local or general anesthesia by repeated aspiration at the posterior iliac crest. It still remains the source of choice for pediatric patients. The discovery of G-

**Leukapheresis** is a process in which white blood cells are filtered out of the blood stream and collected while the remaining blood components are returned to the donor.

CSF and its mobilizing function of CD34<sup>+</sup> cells from the bone marrow into the peripheral blood have resulted in the predominate use of peripheral mobilized stem cells (PMSCs) in adults. Sufficient numbers of PMSCs are easily collected via the antecubital veins by leukapheresis and can be subsequently frozen in liquid nitrogen (< -160°C) until further use. Storage of HSCs

in liquid nitrogen warrants high viability after thawing and facilitates e.g. the usage of autologous HSCs that are collected prior to conditioning therapy. Another positive feature of PMSCs is a quicker engraftment and immune reconstitution as compared with bone marrow grafts [125].

Umbilical cord blood constitutes the third source of graft and was first used in 1988 for alloHSCT between matched siblings in a child with Fanconi's anemia [126]. Cord blood is rich in HSCs and contains more naïve, immature cells [127] as well as immunosuppressive T<sub>Regs</sub> [128]. Potentially due to this multitude of immune regulatory and naïve cells (=more tolerogenic milieu), cord blood transplants cause less GVHD and require less restrictive HLA-matching, however in contrast to autologous transplants a GVT effect is still observed. Despite these premises the success of treatment still increases with better HLA-matching and increasing numbers of HSCs [129]. Since volume of cord blood and number of HSCs is limited, double-unit cord blood transplants are regularly used in order to achieve sufficient HSC numbers suitable for transplantation in adults. In recent studies the co-transplantation of cord blood HSC with HLA-haploidentical peripheral stem cells [130] as well as the *ex vivo* expansion of cord-blood stem cells [131] are under investigation.

#### 3.4.2 Conditioning therapy

For each patient that undergoes HSCT a specific regimen depending on underlying disease and co-morbidities is chosen that conditions or prepares the body for receiving the new immune system. Conditioning therapy comprises three goals: (A) the reduction

of the underlying disease, (B) the depletion of the recipient's bone marrow from the (diseased) hematopoietic system making room for the new immune system, as well as the (C) immunosuppression to avoid immune-rejection especially in alloHSCT. Traditionally, conditioning therapy encompassed a combination of TBI, chemotherapy with cyclophosphamide, which was thought to constitute the main tumor eradicating effect of the treatment. This combination is rather harsh and accompanied with high toxicity that led to the limited application of HSCTs to younger individuals with no severe co-morbidities.

The discovery of the aforementioned curative potential of the GVT effect paved the way for a reduced intensity conditioning (RIC). RIC does not primarily aim to exert an anti-cancer effect but rather aims to prepare the immune system for the transplantation. It therefore solely relies on the immunological eradication of residual cancer cells after transplantation [132]. RIC avoids the high morbidity and mortality caused by early organ toxicity of a standard conditioning regimens thereby allowing alloHSCT in elderly patients with comorbidities. It has however been associated with a higher relapse rate, indicating the importance of a good remission status prior to transplantation [133].

### 3.4.3 Reconstitution of the immune system

The reconstitution of the immune system in terms of versatility, rapidity and quality determines the success of alloHSCT and cancer eradication [134]. The profound immunodeficiency as prevalent in this post-transplant phase holds many severe risks for the patient: (1) occurrence of (opportunistic) infections (see Section 3.5.2 of this chapter), (2) recurrence of the underlying malignant disease due to a missing cancer immunosurveillance and (3) long term development of secondary malignancies [135].

**Opportunistic infections** are infections by pathogens that would not cause infections in a healthy host but take advantage of the in immune-compromised situations of the patient e.g. after HSCT but also AIDS.

Reconstitution is influenced by many factors and events: they can occur (1) before transplantation namely conditioning regimen and type of GVHD prophylaxis, (2) at the time point of transplant (type of transplantation, choice of graft, manipulation of any sort, the degree of histocompatibility (HLA, mHAg, NOD/CARD15 [136])) or (3) after HSCT (presence and grade of GVHD, relapse, infections [137-139]).

The first cells that reconstitute within the first months are the innate immune cells such as neutrophil (mostly first 30 days) and myeloid cells, which are important cells to fight bacterial infections. Interestingly, host derived macrophages are mostly not impacted by conditioning therapy and persist in the tissue. They are replaced by donor-derived macrophages over time [140]. Reconstitution has been predominantly studied in terms of numerical alterations; however decisive for e.g. host defense is the efficient function of the cells. In spite of increasing numbers, neutrophils can be inoperable due to insufficient chemotaxis and phagocytic-bactericidal function for several months [141].

The rapid post-transplant recovery of NK-cells is mostly attributed to an expansion of cytokine producing CD56<sup>bright</sup>CD16<sup>-</sup> NK-cells and takes about 3 months [142].

T- (at least 4 months) and B-cells (at least 9-12 months) take much longer to reconstitute and the complete regeneration of the T- and B-cell compartments can take 1-2 years after HSCT.

In adults the first subtype of T-cells that expands in response to IL-2, IL-7 and IL-15 in the post-HSCT period are the memory T-cells, particularly CD8<sup>+</sup> T-cells [143, 144]. Overall, CD8<sup>+</sup> T-cells exhibit a quicker reconstitution than CD4<sup>+</sup> T-cells [137] leading to an inversed CD4<sup>+</sup>/CD8<sup>+</sup> T-cell ratio compared to healthy persons in the first months [145, 146]. Both residual host memory T-cells that survived conditioning therapy as well as donor memory T-cells in a non-T-cell-depleted graft can give rise to this population [147]. Memory T-cells react against previously encountered pathogens such as herpes viruses (CMV and EBV) and enter more easily tissue than naïve T-cells [148]. However, in order to respond adequately to new immune challenges towards pathogens and tumor antigens, the naïve T-cell repertoire needs to be reconstituted (neothymopoiesis). Since for a complete regeneration, the whole T-cell ontogeny is thymus dependent, involution of thymus due to age seems to play a decisive role. This seems to be especially true for CD4<sup>+</sup> T-cells [149] and as a consequence elderly patients never manage to fully restore the peripheral naïve T-cell receptor repertoire [150, 151]. The population of these lymphocytes leaving the thymus is named recent thymic emigrants (RTE) and can nowadays be monitored according to the signal-joint T-cell receptor rearrangement or T-cell receptor excision circles (TREC) [152]. Low TREC levels have been associated with the aforementioned diminished thymus function due to age, but also by impaired function during opportunistic infections and after alloreactive immune responses in the course of GVHD. A dysfunctional thymus entails an even enhanced GVHD disease activity, since it results in an incorrect selection of T-cell clones respectively fails to effectively deplete auto-reactive T-cells.

Humoral immune responses require a functioning B-cell lineage encompassing B-cell derived plasma cells and memory B-cells. B-cells reconstitute within the first 6 to 9 months [153] and seem to be dependent on a functioning, immaculate bone marrow micro environment. Infiltration of the bone marrow by alloreactive T-cells (GVHD) as well as GVHD immunosuppressive treatment results in a diminished B-cell reconstitution [139]. Furthermore, similar to the T-cell receptor (TCR) repertoire also the immunoglobulin variety (B-cell antibody) seems to be decreased after transplantation [154].

The reconstitution of the immune system is the most decisive step towards cure. A profound understanding of involved underlying processes as well as associated immune impairments will help to adequately cope with many of the subsequently described complications, which originate from an incompetent immune system.

### **3.5 COMPLICATIONS AFTER HSCT**

#### **3.5.1 Early complications**

Early negative effects of HSCT are largely associated with the toxic side effects of the conditioning radio- and chemotherapy and the diminished immune function. In the following paragraphs, some of the most common early complications are described.

Mucositis is a one of the most prevalent problems in patients after HSCT. It is caused by conditioning therapy (= direct tissue damage) and also constitutes a common side

effect of the widely used immunosuppressive agent methotrexate, which preferably targets the fast dividing cells of the mucosa. Oropharyngeal mucositis is very painful regularly requiring opioid-based pain medication. Intestinal mucositis often necessitates parenteral substitution of fluids and calories. Keratinocyte growth factor (KGF) has been used to treat and/or prevent mucositis in some studies showing mixed results [155]. Interestingly, KGF seems to possess a positive effect on thymus function in terms of enhanced thymopoiesis [156].

A very severe, early complication caused by endothelial damage is the hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome. It originates from the hepatotoxic effects of the conditioning regimen, which affects the sinusoidal capillary endothelium. Toxic metabolites that are retained in the liver facilitated by e.g. preexisting liver impairment or due to interactions with other drugs lead to an obstruction of hepatic circulation that causes hepatomegaly, fluid retention and jaundice. Treatment is very difficult and prevention remains the main goal [157]. Defibrotide, which is a deoxyribonucleic acid derivative, has shown some promising results in the treatment of VOD [158].

HSCT-associated thrombotic microangiopathy (TMA) is characterized by anemia, thrombocytopenia, schistocytes and elevated lactate dehydrogenase. It is associated with high mortality (75%) [159]. In contrast to other treatment related adverse events, the intensity of treatment seems to play a minor role in the incidence of TMA. Certain drugs e.g. calcineurin inhibitors, sirolimus [160], viral as well as fungal co-infections, HLA-mismatched donor grafts [161] and aGVHD [162] seem to drive it. Endothelial dysfunction causes microangiopathic hemolytic anemia and platelet consumption. The most decisive therapeutic action is to immediately and completely abrogate calcineurin inhibitors and change of GVHD prophylaxis respectively therapy to e.g. mTOR-inhibitors. The beneficial effect of plasmapheresis and application of thrombolytics has been described in some cases [163].

An early onset of hemorrhagic cystitis is associated with direct toxic effects of the conditioning regimen. Clinical presentation can range from microscopic asymptomatic hematuria, but also very painful, heavy hemorrhage of the entire urine tract has been observed. A later onset is mostly mediated by viral infections (mostly BK polyomavirus, but also adenovirus and CMV) and aGVHD. Hemorrhagic cystitis is normally treated by consequent irrigation and supportive platelet infusions.

### **3.5.2 Infections**

The post-transplant period is coined by an increased risk of infections. It reflects the immune compromised situation of the patient as well as the consequences of intensive pretreatment during conditioning and iatrogenic immunosuppression. The disruption of protective anatomical barriers as skin and mucosa by radio-chemotherapy, mucositis and GVHD together with the usage of plastic catheters further facilitate the entry of pathogens into the body.

The first thirty days after HSCT are characterized by functional asplenia, absent B- and T-cells and most predominantly neutropenia. Neutrophils represent the first line of defense against invading pathogens. Patients are therefore prone to bacterial infections, candida and *Aspergillus* species as well as Herpes simplex virus (HSV). These pathogens often originate from the patient's endogenous gastrointestinal flora, which

led to the prophylactic usage of antibiotics for the so-called selective intestinal decontamination. However, the benefit of this approach has become heavily disputed, since it seems to disrupt the microbial balance of the gut impacting the onset of aGVHD (see following section GVHD).

With rising numbers of neutrophils the incidence of bacterial and fungal infections decreases and infections that are related to the impaired T- and B-cell function dominate. T-cells are vital to prevent viral infections as well as invasive fungal infections. HSCT patients are prone to develop viral infections namely CMV, EBV, adenovirus, BK polyomavirus and respiratory viruses. In addition to newly acquired infections, viruses that reside permanently (and under previous immunologic control) in the patients' tissues such as CMV, EBV, and human herpes virus 6 (HHV-6) reactivate and become pathogenic. CMV and EBV are very common viruses and infections are wide spread among the population. The danger of a life-threatening CMV re-activation has substantially been decreased due to CMV-specific PCR screenings that allow (quantitative) detection of the virus already at a subclinical level and the early initiation of antiviral treatment. Similarly, screening assays for EBV are routinely applied allowing early interventions (by using the anti-CD20 antibody Rituximab), which has significantly reduced the rate of a very severe EBV-associated complication, the post-transplant lympho-proliferative disease (PTLD) [164]. In severe (treatment-resistant) cases of CMV and EBV infections approaches of infusing virus specific T-cells are currently evaluated.


In this phase very intensive prophylaxis is undertaken to prevent fungal infections. It encompasses prophylactic medication, structural precautions (e.g. disinfection routines), and since mold infections are predominantly airborne, isolation rooms and air filters. Again, cellular therapies have been also utilized for treating invasive fungal infections, namely the transfusion of third-party granulocytes but without striking success [165].

### **3.5.3 Graft-versus-host disease**

During the first alloHSCT attempts and especially before the importance of the HLA-system was recognized, severe adverse immunological events were regularly observed and resulted in a deteriorated, life threatening immune reaction. To current understanding, this is mostly mediated by alloreactive T-cells of the graft that react against the host's healthy tissues giving rise to the term graft-versus-host disease (GVHD). The underlying patho-mechanisms share some common features with the beneficial effect of the GVT reaction (Figure 4). The reaction however is amplified to such an extent that it affects healthy tissue and becomes harmful, even life threatening to the host. GVHD remains the greatest cause of morbidity and mortality after alloHSCT and constitutes the biggest hindrance for a successful HSCT.

It occurs depending on the GVHD prophylaxis, mismatch status and previous therapies in 30-60% of all transplanted patients being fatal in about 15% of the cases [119]. The most affected organs are the skin, the gut and the liver, but GVHD can theoretically involve all areas of the body. Traditionally, GVHD was defined as acute when it occurred in the first 100 days after transplantation and chronic GVHD with an onset past day 100 after transplantation. In recent years, it has been challenged whether this classification still applies and there is a tendency to base the classification on the

symptom complex rather than the time-point of onset. Furthermore, a better understanding of the different underlying immunological processes that drive acute and chronic GVHD respectively gains more significance and recognition.



**Figure 4: Graft-versus-tumor (GVT) effect and graft-versus-host disease (GVHD).** Both reactions are mediated by alloreactive donor T-cells. The GVT effect is strongly desired, since it represents the cornerstone for the elimination of residual tumor cells and results in lower relapse rates and better overall survival. GVHD on the other hand represents one of biggest causes for mortality and morbidity after alloHSCT. Highly activated donor T-cells target healthy recipient's tissue with skin, intestine, and liver being the most affected organs.

The pathophysiology of aGVHD is subject to intense research. Still many mechanisms driving aGVHD remain elusive. In the following paragraphs a short outline of today's understanding of the aGVHD pathophysiology is attempted.

GVHD seems to constitute a constringent immunological process that spans three phases [166]: (Phase 1) the initiation of GVHD starts even before transplantation during the conditioning regimen. Radiation as well as chemotherapy damages the host tissue encompassing disruptions of protecting mucosal barriers amongst other in the gut facilitating the entry of pro-inflammatory microorganisms into the body. The resulting inflammation and release of microbial peptides enhances the activation of innate immune cells and results in increased secretion of inflammatory cytokines. These augmented cytokine levels consequently promote an enhanced recognition of host antigens by donor T-cells (Phase two) triggering the activation and proliferation of T-cells. Finally all these processes disembody into (Phase 3) effector cell responses that

damage target organs of GVHD forming a self-amplifying vicious cycle (the GVHD's "perpetuum mobile").

GVHD is predominantly a T-cell driven disease [167], but also NK-cells and macrophages were identified to be involved [123]. Recent evidence indicates that the innate immune system reacting towards microbial peptides holds a pivotal role for GVHD pathophysiology [168].

Several factors that increase the risk of developing GVHD have been identified: they mostly concern matching of recipient and donor (HLA-mismatch, female donors for male recipients, preceding alloimmunisation of the donor), age of recipient, administered conditioning regimen as well as the type of GVHD prophylaxis [169, 170]. Recently, more genetic factors have been found to be associated with the onset of GVHD. Polymorphisms of cytokine-encoding genes [171], differences regarding the pathogen recognition receptors (PPRs) (NOD2/CARD15) [172] and how the body copes with antigens of infective organisms seem to have an important impact on the development of GVHD.

A recent study highlighted the importance of the microbiome respectively its regulators such as paneth cells in the development of aGVHD. Paneth cells reside in the small intestine and regulate the microbial flora by secreting anti-microbial peptides such as defensins and regenerating islet-derived protein 3 alpha (Reg3α) [173]. Lower numbers of paneth cells as well as lower levels of Reg3α correlate with severity of aGVHD and reduced response to GVHD treatment [173, 174]. The loss of regulation in the gut results in a loss of bacterial diversity in favor of increasing prevalence of enterococci [175].

**Microbiome** is a term coined by J. Lederberg "to signify the ecological community of commensal, symbiotic, and pathogenic microorganisms that literally share our body space" [1].

Despite intensive research in terms of developing elegant means for specifically targeting established key players of aGVHD, nowadays steroids that act in a rather non-specific immune suppressive fashion remain the first-line treatment of choice. Taken together, most of the approaches for the treatment and prevention of GVHD have focused on reducing the alloreactivity of donor T-cells. The most potent effect is achieved by depleting donor T-cells from the graft or *in vivo*.

Today most commonly the function of donor T-cells is controlled by immunosuppressive agents firstly the aforementioned steroids, but also other drugs such as calcineurin inhibitors, sirolimus, cyclosporine and methotrexate. Each of them is accompanied by characteristic side effects, ranging from increased infection rates, mucositis, to even renal or liver failure. Overall, 50-60 % of the afflicted patients will respond to an immunosuppressive treatment [92].

Cellular therapy for the treatment of aGVHD is a comparatively novel approach and its use is discussed in the respective sections for MSCs (see section 2), T<sub>Regs</sub> (see section 5) and MDSCs (see section 4).

### **3.6 CONCLUSION**

To date, HSCT transplantation is the most successful immune therapy. It constitutes a grand chance for terminally ill persons to be cured and return to an active life. However, despite the substantial progress that has been made in the last fifty years, many HSCT associated complications remain unresolved and not fully understood. Infections, delayed reconstitution, graft rejection and relapse are often life threatening and remain together with GVHD the major cause of HSCT related morbidity and mortality. Prognosis of high-grade aGVHD is still extremely poor and since the response rate to any treatment decreases with advancing degrees of aGVHD, it appears obligatory to develop means for preventing or at least alleviating the occurrence of severe aGVHD without impairing the GVT effect. The adoptive transfer of MSCs seems to constitute an attractive tool to rebalance the immune system. In the following two chapters, two more cellular populations are introduced that have been implicated to have a beneficial effect on hampering GVHD.




## 4 MYELOID DERIVED SUPPRESSOR CELLS

### 4.1 MDSCs IN HEALTH AND DISEASE

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells at different stages of maturation. They encompass myeloid progenitors, immature granulocytes, DCs and macrophages. Owing to their heterogeneity, human MDSCs cannot be identified by a sole cell-surface-marker guided classification, but only in due consideration of their T-cell suppressive function [176, 177].

MDSCs were first described in the metastatic lymph nodes of head and neck cancer patients [178]. Since early studies focused on tumor diseases [179, 180] elevated frequencies of MDSC and their immunosuppressive effects have been best characterized in malignant diseases of various entities such as hepatocellular carcinoma, renal cancer, melanoma, and breast cancer [181-184].

Increasing evidence suggest that malignant diseases are not a prerequisite for MDSC accumulation. Many immunological situations that involve some sort of inflammatory response such as autoimmunity [185], sepsis and trauma [186], chronic inflammation [187, 188], and also alloHCT [189-191] can elicit increased frequencies of these suppressive cell phenotype. In fact, Hoechst et al. recently identified MDSCs with regulatory properties in the peripheral blood of healthy individuals [192] further corroborating the notion that MDSCs hold a physiological role in immune homeostasis similar to T<sub>Regs</sub>. In healthy individuals MDSCs constitute only a very low percentage (about 0.5%) of the total peripheral blood mononuclear cells (PBMCs) [180, 193] and quickly differentiate into mature granulocytes, macrophages and DCs. However, immunological conditions as found in cancer and inflammation seem to create an environment that leads to the enhanced mobilization and accumulation of these cells.



**Figure 5: Two-step model of expansion and activation of MDSCs.** Cytokines and growth factors, which are present in inflammatory processes such as TNF- $\alpha$ , IFN- $\gamma$ , G-CSF and interleukins, mediate the expansion and activation of MDSCs.

Accumulation of MDSCs appears to involve two consecutive steps (Figure 5):

1. Cytokines and growth factors that are abundant during inflammation such as TNF- $\alpha$ , G-CSF, GM- or M-CSF [194], IL-6 [195], PGE<sub>2</sub> [196, 197], but also complement factors (C5a) [198] and cytokine-like pro-inflammatory proteins such as S100A8/A9 [199] cause an expansion and mobilization of immature myeloid cells [200, 201].
2. The second signal, which leads to the activation and inception of their suppressive function, occurs in the periphery. Myeloid progenitors come in contact with inflammatory cytokines such as IL-4, IL-6, IL-13, IFN- $\gamma$ , and TGF- $\beta$  that induce suppressive pathways. These triggering cytokines are secreted by activated cells and in the case of malignant disease by tumor (associated) cells. Besides activation, this cytokine-“cocktail” also promotes a differentiation arrest (by e.g. activation of the transcription factor signal transducer and activator of transcription (STAT)3) [200-202]. On the basis of inter-individual biological variability respectively the distinct biology of various malignancies, the composition of these cytokines differs. This might explain the plethora of described (some time inconsistent) MDSC-phenotypes.

Self-evidently it is extremely difficult to prove this two-signal model of expansion and activation *in vivo* [203]. The pivotal role of the surrounding immunological milieu however has been demonstrated indirectly in *in vitro* studies. Bone marrow derived MDSCs exhibit an increased proliferation rate in the presence of activated T-cells, which also impeded further maturation of MDSCs [204]. Furthermore, immunosuppressive MDSCs can be induced from healthy donor derived CD14<sup>+</sup> monocytes in the presence of tumor cells or by addition of a cocktail including several of the aforementioned cytokines and growth factors [195, 196, 200, 201, 205]. Upon removal from the tumor milieu, MDSCs can partially differentiate into normal DCs and macrophages [206-208] indicating the importance of the extrinsic signals and lack of a genetic imprinting.


Besides the initiation, activation and differentiation arrest of MDSCs, activated T-cells seem to represent a checkpoint for their expansion. Similar to T-cell homeostasis in which activation always also partially results into an increased cell death (AICD), it was shown for murine granulocytic, Fas<sup>+</sup> MDSCs that Fas-FasL interaction with activated T-cells led to a caspase mediated apoptosis in Fas<sup>+</sup>MDSC [209].

Interestingly, MDSCs are not only ‘passively’ expanded in response to their environment. MDSCs themselves might actively promote their own accumulation within an autocrine feedback loop, as paradigmatically shown for MDSCs isolated from ovarian and prostate cancer patients. These cells secrete IL-10, which amongst other effects, causes the sequestration of HLA-DR and consequently leads to higher frequency of HLA-DR<sup>low/neg</sup> monocytic MDSCs [210].

## 4.2 PHENOTYPE

In the mouse MDSCs are defined by the expression of the myeloid lineage differentiation antigens Gr-1 and CD11b [211]. Based on the level of Gr-1 expression,

MDSCs are subdivided in a  $CD11b^{+}Gr1^{high}$  ( $CD11b^{+}Ly-6G^{+} Ly-6C^{low}$ ) expressing granulocytic and a  $CD11b^{+}Gr1^{low}$  ( $CD11b^{+}Ly-6C^{high}Ly-6G^{-}$ ) monocytic MDSC subset [212]. In contrast to murine MDSCs their human counterparts lack specific markers and are therefore much harder to define phenotype wise [187]. As yet, a steadily growing number of phenotypes have been described in various pathological conditions [213]. Consensus is that human MDSCs are displaying a lack or at least significantly decreased levels of markers characteristic for mature myeloid cells [214]. Furthermore, they regularly have a pronounced expression of CD11b an integrin required for monocytes and neutrophils to interact with the endothelium, the transmembrane receptor CD33 and display - in a non-typical fashion for myeloid cells - an absence or a very low expression of HLA-DR [193, 215].



**Figure 6: Gating strategy to identify  $CD14^{+}HLA-DR^{low/neg}$  MDSCs.** This FACS blot exemplifies how frequencies of MDSCs can vary between a healthy donor (HD) and a person that experiences some kind of inflammatory reaction in this case alloHSCT (Pat) [190].

In recent attempts to categorize human MDSCs, the cells have been grouped based on the expression of the LPS co-receptor CD14, into monocytic ( $CD14^{+}HLA-DR^{low/neg}CD33^{+}$ ) [216-218] and granulocytic MDSCs (lineage negative ( $CD3, CD14, CD19, CD56$ ))  $CD33^{+}HLA-DR^{low/neg}$  [176, 177]. These two subpopulations can occur exclusively but overlaps have also been reported [219, 220]. Multiple phenotypes have been described in different diseases [221] indicating that the population of MDSCs is shaped by their surrounding micro milieu as afore described in more detail.


Marker	Function	Reference
CD80, CD83, DC sign	Co-stimulatory molecules	[183, 222]
IL-4 receptor $\alpha$ (CD124)	Activation and suppression	[223-225]
M-CSFR (CD115)	Growth factor receptor	[224, 226]
TNFRII	MDSC accumulation, apoptosis inhibition	[203, 227]
VEGFR1		[177, 228]
CD15, CD66b	Granulocytic marker	[177, 229, 230]
CD62L	Adhesion molecule	[177, 190, 231]
CD49d	Integrin	[232]
CD16	Fc receptor	[177]
CCR2 (CD192)	Chemokine receptor	[227]

**Table 4: Phenotypic markers that have been described for human MDSCs.**

### 4.3 T-CELL SUPPRESSIVE ACTIVITY

MDSCs exhibit a plethora of direct and indirect mechanisms to suppress T-cell activation and proliferation [233, 234] (Figure 7). This diversity seems to be partially attributed to their monocytic or granulocytic nature, maturation and activation status and is consequently shaped by their surrounding microenvironment similar to their phenotype. Most likely, MDSCs constitutively exhibit more than one suppressive pathway, however since most investigators concentrated on the most distinguished, protruding suppressive mechanism the co-existence of several suppressive mechanisms has only been evaluated in few studies [183, 235].

The basic question regarding an antigen-specific MDSC-mediated suppression has not been completely resolved. Interestingly, MDSCs are able to take up and process soluble antigens and to subsequently present them to T-cells [231, 236]. Since antigen-presentation by MDSCs is - unlike in professional APCs inadequate (e.g. lack of co-stimulation) - it is speculated whether it represents a very elegant method for inducing tolerant  $CD4^+$  and  $CD8^+$  T-cells in an antigen-specific manner [204].



**Figure 7: Immune suppression exerted by MDSCs.** MDSCs release a plethora of immune regulatory factors such as IL-10, TGF-β and express enzymes such as inducible nitric oxide synthetase (iNOS) and Arginase-1 (ARG1) that deplete arginine an essential amino acid for T-cell activation from the environment. MDSCs produce furthermore reactive oxygen species (ROS) via NADPH oxidase (NOX2) that react with nitric oxide (NO), which is released by the metabolism of L-arginine by iNOS. This forms the radical peroxynitrite (ONOO<sup>-</sup>).

### 4.3.1 Lymphocyte nutrient depletion

One of the first identified mechanisms of MDSC-mediated suppression involved the metabolism of the essential amino acid arginine. L-Arginine is utilized for protein synthesis and plays a decisive role for T-cell activation (TCR-signaling) and proliferation.

In MDSCs two enzymes have been identified that lead to arginine depletion: arginase 1 (ARG1) [237] and inducible nitric oxide synthetase (iNOS). First, cells take up arginine by the cationic membrane transporters (CATs). Next, ARG1 metabolizes arginine into ornithine and urea thereby depleting it from the environment and additionally generating immune regulatory metabolites (e.g. putrescine, L-proline) [215, 238]. Uptaken arginine is converted by iNOS [200] into citrullin while nitric oxide (NO) is released. Interestingly, the expression of these two enzymes seems to be competitively regulated [239] and they are normally not simultaneously active in the same cell. Furthermore, in some cell populations (e.g. macrophages) expression of ARG1 and iNOS seem to be linked to maturation [240, 241].

MDSC-mediated arginine deficiency impairs the proliferation and IFN- $\gamma$  production of T-cells [181, 183] and leads to a decreased CD3 $\zeta$ -chain expression. CD3 $\zeta$ -chain is decisive for T-cell signaling and its decreased expression results in impaired T-cell signal transduction [242]. In a murine GVHD model, ARG1

**CD3 $\zeta$ -chain (CD247)** is a key component for signal transduction of the TCR. It contains three immunoreceptor tyrosin-based activation motifs that transduce activation upon antigen recognition to intracellular signaling. Low expression of CD3 $\zeta$ -chain results in impaired T cell activation.

**A cell cycle or cell division cycle encompasses** sequential events involved in cell division: (1) quiescent G<sub>0</sub>-Phase, (2) Interphase, ('preparatory phase') encompassing G<sub>1</sub>-Phase, S-Phase, G<sub>2</sub> Phase and the cell division itself (3) mitosis


activity of MDSCs could significantly inhibit T-cell activation, proliferation and inflammatory cytokine release [189]. One underlying mechanism of the observed effects of L-arginine starvation on T-cells could be an impaired up-regulation of cell cycle regulators cyclin D3 and cyclin dependent kinase 4 (cdk4) which results in a cell cycle arrest in the G<sub>0</sub>-G<sub>1</sub> phase [238]. ARG1 mediated effects could be abolished *in vitro* by the exogenous L-arginine

addition or inhibition of ARG1 with nor-NOHA (N $\omega$ -hydroxy-nor-arginine) and L-NMMA (L-NG-monomethyl arginine acetate) [183, 243].

Nitric oxide (NO) release leads to the impaired activation and function of T-cells. It inhibits for example Janus kinase (JAK) 3 and STAT5 signaling [244] and suppresses the expression of HLA-DR [245]. It also has been associated with the induction of T-cell apoptosis [246]. Furthermore, in the presence of reactive oxygen species (ROS), NO is converted to peroxynitrite (ONOO<sup>-</sup>). Peroxynitrite is a radical that randomly interacts with proteins causing nitration. In a mouse model, it was demonstrated that this nitrotyrosine accumulation also occurs in the TCR-region. It impairs HLA-class mediated antigen recognition resulting in an impaired T-cell response [236].

ARG-1 and iNOS expression seems to be impacted by the surrounding environment. Inflammation accompanied by the secretion of cytokines such as IFN- $\gamma$ , IL-4 and IL-13 by activated effector cells might be involved in the up-regulation of ARG-1 activity respectively the induction of iNOS [189, 247]. IFN- $\gamma$  is known for its activating impact

on the transcription factor STAT1, which is responsible for the up-regulation of iNOS and ARG1 in MDSCs. Furthermore the link of IFN- $\gamma$  and STAT1 could be one reason that strongly activated T-cells are more easily suppressed by MDSC [204] and blocking of IFN- $\gamma$  abolishes the suppressive capacity of MDSCs [231, 248]. Up-regulation of iNOS/ARG1 has also been associated with STAT6 activation increasing the suppressive function of MDSC [247] (Figure 8).



**Figure 8: STAT signaling pathways involved in the expansion and activation of MDSCs.** Cytokines and growth factors that are released in inflammation and malignant diseases such as IL-6, IL-4, G-CSF and VEGF activate the family of STAT transcription factors. STAT3 plays a central role for a differentiation arrest, which together with an enhanced myelopoiesis leads to MDSC accumulation. STAT1, STAT3, and STAT6 activation promote the up-regulation of immunosuppressive enzymes such as iNOS, ARG1, and COX-2 as well as to the increased production of suppressive cytokines such as TGF- $\beta$  and MDSC-inducing factors such as IL-6, IL-10 and G-CSF. Increased ROS production, which has been shown to favor myeloid differentiation arrest and T cell suppression, is observed upon STAT1, STAT3 and STAT6 activation.


#### 4.3.2 Oxidative stress

Reactive oxygen species (ROS) such as hydrogen peroxides or superoxide anions are main by-products of the cellular respiration (in the mitochondria) and furthermore produced by the membrane bound enzyme complexes of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Figure 9). ROS is a double-edged sword in immunology [249]:

**Reactive Oxygen Species (ROS)** encompass superoxide ( $O_2^-$ ), hydrogen peroxide ( $H_2O_2$ ), hydroxyl radicals ( $OH^\cdot$ ), and instable products that result from lipid peroxidation. ROS readily damage intracellular targets such as DNA, carbohydrates and proteins and has to be balanced by the cellular anti-oxidants.



ROS play a central role in cell signaling as an important second messenger and also possess a direct role in immune function, in particular in the elimination of pathogen by phagocytes via the so-called oxygen burst. However, a constant, increased production of ROS, which outweighs the cellular anti-oxidative capacity epitomized by the thiol-containing molecules glutathione, and several ROS-metabolizing enzymes such as catalase or superoxide dismutase, results in oxidative stress. Oxidative stress causes inter alia potent immunosuppression and constitutes one of the known tumor escape mechanisms. It inhibits the recruitment of CTLs [250] and suppresses T-cell function [251]. Interestingly, immune suppressive T<sub>Regs</sub> exhibit an enhanced resistance to oxidative stress [235].



**Figure 9: Composition of nicotinamide adenine dinucleotide (NADPH) oxidase.** NADPH oxidase is a transmembrane enzyme complex that produces superoxide anions upon activation. It consists of six subunits: Rho related C3 (Rac) and five phagocytic oxidase (phox) units: gp91, p22, p47, p40 and p67. NADPH oxidase plays a pivotal, physiological role in microbial defense by neutrophils. In various malignant and inflammatory diseases, an immoderate activity of NADPH oxidase is observed in various cell types and tissues. This results in an excessive production of superoxide leading to oxidative damage of DNA, proteins, and lipids and immune alterations

MDSCs, especially the granulocytic subsets have been shown to regularly exhibit an increased production of ROS [211, 229]. MDSCs produce ROS mainly via the NADPH oxidase [252] and an up-regulation of its subunits gp91 and p47 was observed for MDSCs in patients with advanced melanoma [183]. ROS serves several functions for MDSCs: (1) suppression of the immune system as demonstrated for antigen specific CD8<sup>+</sup> T-cells [211, 252], and induction of apoptosis in activated T-cells by decreasing

Bcl-2 expression [253]. In fact, antagonizing ROS by using for example the ROS metabolizing enzyme catalase can revert MDSC-mediated suppression by increasing IFN- $\gamma$  production of T-cells in presence of MDSCs [211, 220]. The second function ROS holds is the (2) promotion of MDSC expansion: ROS abets the phosphorylation of the transcription factor STAT3. STAT3 plays a pivotal role for several aspects in MDSC immunology. It controls the suppressive activity of MDSCs as well as the myelopoiesis and blocks their further differentiation into granulocytes, macrophages and DCs [183, 200, 252] (Figure 8).

Inflammatory cytokines such as IL-3, IL-6, IL-10, GM-CSF [254], but also cytokines secreted by MDSCs themselves as TGF- $\beta$  promote ROS production within an (autocrine) feedback loop [183].

#### **4.3.3 Alternative suppressive mechanisms**

The suppressive activity of MDSC has been associated with the production of various immune regulatory cytokines such as IL-10 [197], TGF- $\beta$  [255, 256] and PGE<sub>2</sub> [257]. These cytokines play a role in direct immunosuppression and have been associated with the MDSC driven tumor promotion [255, 258, 259], and induction of T<sub>Regs</sub> (see following section).

Recently, CD14<sup>+</sup>HLA-DR<sup>low/neg</sup> MDSCs have been identified in breast cancer [184], but also in GHVD which exhibited an increased expression of IDO [190]. IDO is an enzyme, which metabolizes tryptophan an essential amino acid to kynurenine-pathway metabolites. Low tryptophan levels leads amongst other to the inhibition of the mTOR kinase pathway. Furthermore, the resulting kynurenine metabolites namely, 3-hydroxyanthranilic acid and quinolinic acid, hold immune regulatory properties [260]. IDO plays an important role for acquired peripheral tolerance and the control of severe inflammation [261]. One characteristic is its quick upregulation respectively inducement upon inflammatory stimuli such as IFN- $\gamma$  [262].

#### **4.3.4 T-cell differentiation and trafficking**

MDSCs do not only directly suppress T-cell responses but also amplify their immunosuppressive capacity by the T<sub>Regs</sub> induction [225, 263] and expansion of antigen-specific nT<sub>Regs</sub>. The exact mechanisms have not been elucidated but production of cytokines such as IFN- $\gamma$ , TGF- $\beta$  and IL-10 [225, 263] as well as direct cell-cell interactions via CTLA4 [222] and CD40-CD40L interactions [264] seem to play a role. T<sub>Regs</sub> play an important role in regulating the immune responses and their expansion in cancer constitutes one of the well-established immune escape mechanisms [265]. This T<sub>Regs</sub> inducing function is albeit not limited to MDSCs in cancers [181, 225, 263], but also utilized by immature myeloid cells in healthy persons to orchestrate the immune system: It was shown that CD14<sup>+</sup>HLA-DR<sup>-</sup> cells induce in CD4<sup>+</sup> T-cells the production of IL-10 and convert conventional T-cells into FoxP3<sup>+</sup>T-cells while promoting the transdifferentiation of Th17-cells into iT<sub>Reg</sub> [192].

Furthermore, MDSCs confine the trafficking of T-cells to secondary lymphoid organs, which is a key step for the T-cell priming. Expression of CD62L (L-Selectin) allows cells to enter secondary lymphoid organs. MDSCs have been shown to decrease the CD62L expression on naïve T-cells by tumor necrosis factor- $\alpha$ -converting enzyme (TACE) thereby hampering their priming in secondary lymphoid organs [266]



#### 4.4 CONCLUSION


MDSCs have emerged as an important immune regulatory population that exists physiologically at low frequencies. In situations of immune activation such as inflammation, cancer or within the framework of an emergency myelopoiesis MDSCs can accumulate. Due to the plethora of identified phenotypes in human diseases, a sole phenotypic identification does not suffice to reliably identify these cells. To experimentally prove their immunosuppressive function towards T-cells is pivotal for naming them MDSCs.

Taken together, similar to  $T_{\text{Regs}}$ , described in the next chapter, MDSCs might be - according to the given condition - a friend (trying to control acute inflammation) or a foe (suppressing immune responses against cancer cells). In the future, it will be of great interest to further delineate the underlying mechanisms responsible for their expansion and activation as well as their immune suppressive strategies. These insights could provide the sound basis for developing strategies to target specifically MDSCs or to exploit their therapeutic potential (e.g. in GVHD).

## 5 REGULATORY T-CELLS

The maintenance of self-tolerance and immune regulation is largely attributed to a suppressive subpopulation of T-cells. The existence of so-called suppressor T-cells was first described by Gershon et al. in 1970 [267]. It took however another 25 years until Sakaguchi et al. could identify a specialized subset of  $CD4^+CD25^+$  T-cells that could prevent autoimmune disease in a murine model [268]. Based on their immune regulatory function in maintaining tolerance to auto- and alloantigens, these cells were named regulatory T-cells ( $T_{Reg}$ ) [269].

$T_{Reg}$ s are primarily classified according to their origin (Figure 10):  $T_{Reg}$ s that derive from the thymus are named natural occurring  $T_{Reg}$ s ( $nT_{Reg}$ s) and  $T_{Reg}$ s that are induced from activated conventional T-cells ( $T_{Conv}$ ) in the periphery are called induced  $T_{Reg}$ s ( $iT_{Reg}$ s). The exact mechanisms how  $iT_{Reg}$ s are induced from  $T_{Conv}$  have not yet been deciphered, but two pivotal aspects have been ascertained to promote their generation: (1) inadequate antigen presentation (2) and the presence of high levels of cytokines such as IL-2, IL-10, and TGF- $\beta$  [265]. Several studies have reported that  $T_{Reg}$ -induction can also be cell-mediated. Immunosuppressive cell populations such as MSCs [31, 48] (see section Chapter 2), MDSCs [192] (see Chapter 4) and even  $nT_{Reg}$ s [270] appear to amplify their own suppressive capacity (in terms of cell numbers but also duration of suppressive activity) by inducing additional regulatory phenotypes.




**Figure 10: Origin of regulatory T cells ( $T_{Reg}$ ).** Natural occurring  $T_{Reg}$ s develop in the thymus from T cell progenitors (thymocytes). Furthermore,  $T_{Reg}$ s can be induced from mature conventional T cells in the periphery as here depicted for  $CD4^+$  T cells, which can be induced to become e.g. IL-10 $^+$  Tr1 cells or TGF- $\beta^+$  Th3 cells. Several suppressive cells such as MSC and MDSC as well as the presence of high levels of cytokines namely IL-2, TGF- $\beta$  and IL-10 in combination with inadequate antigen stimulation mediate this process.

## 5.1 PHENOTYPES

One of the first phenotypic markers for defining nT<sub>Regs</sub> was the high expression of CD25, which is the alpha-chain of the high-affinity receptor for IL-2 [271]. IL-2 is secreted by stimulated T-cells [272] and drives their proliferation and clonal expansion [273]. Although nT<sub>Regs</sub> themselves are normally anergic and do not produce IL-2 upon stimulation, IL-2 plays an essential role for T<sub>Regs</sub> function, proliferation and survival. IL-2 seems to reconstitute a feedback circuit: activation of T-cells simultaneously promotes the existence of T<sub>Regs</sub> and furthers their immunosuppressive function [274]. Furthermore, the high consumption of IL-2 by T<sub>Regs</sub>, results in shortage of IL-2 for naïve and effector T-cells leading to their apoptosis [275]. This has been proposed to represent an immunosuppressive feature of T<sub>Regs</sub>.

Since CD25 expression can also be increased on activated T<sub>Conv</sub> cells, CD127 (IL-7R $\alpha$  chain) was added to the panels for identifying nT<sub>Regs</sub>. It has been shown that nT<sub>Regs</sub> (unlike activated T-cells) express CD127, if at all only at low levels [276], which in addition correlates inversely with the expression levels of the transcription factor FoxP3 [277]. FoxP3 has been identified as the prototypic master regulator for nT<sub>Regs</sub> and represents one of the most reliable (intracellular) phenotypic markers of nT<sub>Regs</sub> [278]. nT<sub>Regs</sub> depend on a high and continuous expression of FoxP3 for their development and suppressive function [279]. The key function of FoxP3 and nT<sub>Regs</sub> for immune homeostasis can be observed in the so-called IPEX syndrome (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome), which is associated with heavy autoimmunity and is frequently lethal in the first years of life [280]. The human IPEX locus was identified as Xp11.3-Xq13.3 [281] and IPEX mutations may lead to alterations in the forkhead motif in the FOXP3 coding region. Recent studies emphasize the role of the methylation status of the FOXP3 promoter region [282]. This data suggests that methylation analyses could represent an even more accurate method (than FACS) for identifying and even quantifying “pure” nT<sub>Regs</sub>. But obviously more research and development is required for introducing such method into the clinical or laboratory routine.



**Figure 11: Phenotypic characterization of naturally occurring T<sub>Regs</sub>.** This figure shows a representative example for the FACS Blot gating strategy for nT<sub>Regs</sub>. Gating on CD3<sup>+</sup>CD4<sup>+</sup> T-cells is followed by the identification of the CD25<sup>hi</sup>CD127<sup>low/neg</sup> subpopulation, which expresses the transcription factor FOXP3 (depicted as histogram, grey = isotype control) [51].

The afore described phenotypic markers are characteristic for nT<sub>Regs</sub> and do not necessarily apply for iT<sub>Regs</sub> (Table 5), which sometimes express only low levels respectively no FOXP3 and CD25 [265, 283]. The two most frequently described subsets of iT<sub>Regs</sub> are mostly defined by their high expression of the immune modulating cytokines IL-10 (IL-10<sup>+</sup> T<sub>Reg</sub>1 cells (Tr1 cells)) and TGF- $\beta$  (TGF- $\beta$ <sup>+</sup> T helper (Th) 3) [265] upon antigen-stimulation.

Cell Type	Origin	Phenotype	Suppressive mechanisms
<b>nT<sub>Regs</sub></b>	<b>Thymus</b>		
CD4 nT <sub>Regs</sub>		CD4 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup> CD127 <sup>low</sup> CTLA4 <sup>+</sup> LAG-3 <sup>+</sup> GITR <sup>+</sup>	contact, cytotoxicity, IL-10, TGF- $\beta$
CD8 nT <sub>Regs</sub>		CD8 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup> CTLA4 <sup>+</sup> CD122 <sup>+</sup>	contact
<b>Adaptive/ Induced T<sub>Regs</sub></b>	<b>Periphery</b>		
CD4 nT <sub>Regs</sub> like		CD4 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup> CTLA4 <sup>+</sup> GITR <sup>+</sup>	contact (requires IL-2 and TGF- $\beta$ )
Tr1		CD4 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup>	IL-10
Th3		CD4 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup>	TGF- $\beta$ , IL-10 (to a lesser extent)
CD8 iT <sub>Regs</sub>		CD8 <sup>+</sup> CD25 <sup>+</sup> FOXP3 <sup>+</sup>	IL-10, TGF- $\beta$
CD8 iT <sub>Regs</sub>		CD8 <sup>+</sup> CD25 <sup>+</sup> CD28 <sup>+</sup> FOXP3 <sup>+</sup> CTLA4 <sup>+</sup> GITR <sup>+</sup>	contact, IL-10, ILT3, ILT4

**Table 5: Regulatory T-cell subsets and suppressive mechanisms.** Different regulatory T-cells subsets have been identified which differ in phenotype as well as their mode of immunosuppression. *Adapted from* [265].


## 5.2 SUPPRESSIVE MECHANISMS

T<sub>Regs</sub> suppress as demonstrated in numerous *in vitro* and *in vivo* studies the activation and expansion of cells from the innate and adaptive immune system, thereby impacting cellular and humoral immune responses. Several prerequisites have to be met for T<sub>Regs</sub> mediated suppression as (1) physical proximity to target cells, (2) sufficient number of T<sub>Regs</sub> and (3) preceding activation of T<sub>Regs</sub> by TCR-ligation [284-286]. T<sub>Regs</sub> activation is antigen specific, however once they are activated their suppression is antigen independent (“bystander suppression”) [285]. Interestingly, in order to prevent autoimmune disease and maintain immunological self-tolerance, T<sub>Regs</sub> might even be “auto-reactive” in terms of (self-) antigen specificity, which warrants a continuous stimulation by self-antigens [284].

Several soluble factors such as immune regulatory cytokines most notably IL-10 and TGF- $\beta$  are released by activated T<sub>Regs</sub>. Both cytokines seem to play a pivotal role in

$T_{\text{Regs}}$  mediated suppression *in vivo*, as it has been e.g. shown for IL-10 in a murine model for autoimmune diseases [287, 288]. In most *in vitro* models, secretion of TGF- $\beta$  and not IL-10 was observed in most  $nT_{\text{Regs}}$ -cultures [289]. The existence of TGF- $\beta^+$  Th3 cells were first mentioned in association with the inhibition of Th1-cells via secretion of TGF- $\beta$  in a murine MS model [290] with their importance being recognized in several autoimmune disease models in the following years [291].

Besides direct suppression, TGF- $\beta$  and IL-10 foster the induction of additional immune regulatory cells such as IL-10 $^+$  Tr1 cells and TGF- $\beta^+$  Th3 cells from naïve T-cells at the site of action [265, 270]. Present data indicates that these  $iT_{\text{Regs}}$  play a physiological role in the maintenance of tolerance in the gut environment and inflammatory responses. A similar effect as IL-10 and TGF- $\beta$ , has PGE $_2$ , which is generated by COX-2 and mainly released by  $iT_{\text{Regs}}$ : it leads to the induction of an immune regulatory phenotype in CD4 $^+$  T-cells [292] and furthermore suppresses effector T-cells [293].



**Figure 12: Suppressive mechanisms identified for regulatory T cells ( $T_{\text{Regs}}$ ).**  $T_{\text{Regs}}$  secrete suppressive cytokines such as IL-10, PGE $_2$  and TGF- $\beta$ , which directly suppress effector T-cells ( $T_{\text{eff}}$ ), but also further promote induction of  $iT_{\text{Regs}}$ . CTLA4 expressed on the  $T_{\text{Reg}}$ -surface directly inhibits DCs. Furthermore  $T_{\text{Regs}}$  express high levels of CD25 that is part of a high affinity receptor for IL-2 (IL-2R). Thereby they can outcompete activated T-cells in terms of IL-2 uptake leading to the anergy of the activated T-cells and cell death.  $T_{\text{Regs}}$  can also directly kill conventional T-cells by injecting toxic levels of cyclic adenosine monophosphate (cAMP) via membrane gap junctions or in a granzyme B/perforin dependent way.  $T_{\text{Regs}}$  furthermore deplete the environment of adenosine triphosphate (ATP) by metabolizing it into adenosine a potential suppressant of T-cells by ectoenzymes (CD39 and CD73).

Furthermore, the elevated levels of all these cytokines lead to a suppressive, tolerogenic milieu by reducing the capacity of APCs to induce alloantigen-specific T-cells [289, 290]. These suppressive effects can also be observed in the tumor microenvironment, which in this case hinders anti-tumor immune responses [265]. Recently, IL-35, which belongs to the IL-12 heterodimeric family was identified as an essential player for the full suppressivity of T<sub>Regs</sub> [294]; however so far its role has been mostly identified in the murine system, while its impact on the suppressive capacity of human T<sub>Regs</sub> as well as its effect on other cells than T-cells has not been elucidated.

The role of IL-2 consumption by high affinity receptor CD25 leading to IL-2 starvation as a mean of T<sub>Reg</sub> mediated suppression has been subject of debate. A recent study has shown that IL-2 deprivation leads to apoptosis [275], however IL-2 depletion does not seem to be the premise for effector T-cell suppression [295].

T<sub>Regs</sub> express several inhibitory receptors such as fibrinogen-like protein 2 (FGL2), cytotoxic T-lymphocyte antigen 4 (CTLA4) and lymphocyte-activation gene 3 (LAG-3). CTLA4 and LAG-3 are constitutively expressed on nT<sub>Regs</sub>. They have direct inhibitory effects on T-cells and also indirect T cell regulating effects by modulating APC function: CTLA4 is a ligand for accessory molecules (such as CD80/CD86) expressed on activated T-cells and its binding to the T-cell transmits an inhibitory signal. Furthermore, CTLA4 binding to CD80/CD86 on DCs seems to lead to their down-regulation of these co-stimulatory molecules in a negative feedback manner. This leads to a decreased T-cell stimulation. T<sub>Regs</sub> furthermore impair DC maturation by e.g. binding of LAG-3 to HLA-Class II molecules, which are expressed on several types of APCs. This LAG-3 binding induces a negative signal for the maturation of APCs [265]. CTLA4 on the other hand can amplify its suppressive effects on T-cell activation and function by the induction of IDO in APCs [296]. IDO metabolizes tryptophan into kynurenine and several immune regulatory metabolites. FGL2 has been shown to induce B-cell apoptosis thereby decimating their interaction with activated T-cells [297, 298].

Cyclic adenosine monophosphate (cAMP) is an important second messenger for cell signaling. T<sub>Regs</sub> utilize cAMP injections via membrane gap junctions into target cells to impair T-cell proliferation and IL-2 production [299]. T<sub>Regs</sub> can also alter the levels of cAMP by influencing the extracellular nucleotide/nucleoside levels of for example adenosine by CD39 (ecto-nucleoside triphosphate diphosphohydrolase) and CD73 (ecto-5'-nucleotidase) [300] expressed on their cell membrane. Adenosine inhibits function of T-cells through the adenosine receptor 2A [301]. Furthermore, it has been shown that T<sub>Regs</sub> also utilize ROS produced by NADPH oxidase in conjunction with TGF- $\beta$  to suppress CD4<sup>+</sup> effector cells [302].

Direct cytolysis of effector cells mediated by T<sub>Regs</sub> is accomplished by the perforin-granzyme pathway or by the induction of apoptosis by TRAIL-DR5 pathway [301]. Granzymes are serine proteases that utilize perforin to enter target cells, where they induce apoptosis by cleaving important substrates. Several studies have shown that T<sub>Regs</sub> induce cytolysis in monocytes T-, B- and NK-cells as well as CTLs in a granzyme B dependent manner [265, 301, 303, 304]. However, if the induction of apoptosis is a pivotal suppressive mechanism *in vivo*, has yet to be clarified.

### 5.3 THERAPEUTIC POTENTIAL FOR T<sub>Regs</sub> IN THE TREATMENT OF GVHD

The adoptive transfer of T<sub>Regs</sub> has gained momentum as a mean to treat GVHD following the seminal studies carried out by Edinger et al. In murine mismatched alloHSCT models, it has been shown that the ratio of T<sub>Regs</sub> to CD4<sup>+</sup> T<sub>conv</sub>-cells strongly determines the outcome of GVHD [305, 306]. Furthermore, it has been shown that this ratio (T<sub>Regs</sub> to CD4<sup>+</sup> T<sub>conv</sub>-cells) plays an important predictive role for long-term graft tolerance in alloHSCT and also liver and kidney transplantations [307]. Many immune monitoring *ex vivo* studies concluded that humans that have lower frequencies of T<sub>Regs</sub> in the peripheral blood after HSCT hold a higher risk of developing GVHD [308, 309]. This was not only the case for diminished thymic derived nT<sub>Regs</sub> but also IL-10<sup>+</sup> Tr1 T<sub>Regs</sub> [310], which has been associated with increased intestinal inflammation [289].

In animal models it has been shown that T<sub>Regs</sub> suppress hyperactive, autoreactive T-cells (GVHD) while maintaining the GVT effect [311, 312] and without impairing antiviral T-cell immunity [313].

One important prerequisite for a successful adoptive cellular therapy is to gain sufficient numbers of the transferred cells. Different approaches have been undertaken ranging from *in vitro* expansion of cord blood units [314], to *ex vivo* isolation of CD4<sup>+</sup>CD25<sup>+</sup> T<sub>Regs</sub> [315, 316]. The first clinical studies showed a beneficial effect without an increased relapse or higher infection rate [314-316]. Another issue that has to be resolved which is the best time point, the optimal cell dose for transfusion and what phenotype of T<sub>Regs</sub> is associated with the highest suppressive capacity and should therefore be preferentially selected. CD4<sup>+</sup>CD25<sup>high</sup> T<sub>Regs</sub> that also express CD45RA, inducible T-cell costimulator (ICOS) and are negative for CD127 seem to be most suitable [317]. Infusion numbers range from 100,000 to 1,000,000 T<sub>Regs</sub> per kg body weight [314, 316, 318]. Interestingly, it seems to depend on the utilized expansion protocol, if these numbers are sufficient and effective.

Recently, it was shown that in patients with chronic GVHD low dose treatment with IL-2 (0.3×10<sup>6</sup> to 1×10<sup>6</sup> international units (IU) per square meter of body-surface area) leads to *in vivo* expansion of T<sub>Regs</sub> [319]. It is thought that this low dose of IL-2 stimulates specifically T<sub>Regs</sub> due to their higher affinity for IL-2 as compared to conventional T-cells. The clinical effects were promising and therefore further studies have to show whether the *in vivo* induction of T<sub>Regs</sub> could represent a (more convenient) Treg-based approach than *ex vivo* expansion with following adoptive cell transfer.

### 5.4 CONCLUSION

Regulatory T-cells (T<sub>Regs</sub>) represent a pivotal checkpoint for the immune system preventing auto-immunity and chronic inflammation. In addition to the well-established thymus-derived naturally occurring nT<sub>Regs</sub>, T<sub>Regs</sub> can be induced from regular T<sub>Conv</sub> cells by a number of cytokines (e.g. IL-10) and other cell types (e.g. MDSCs). This so-called “on-site” generation is an elegant mean for a timely and most likely locally restricted reaction against inflammatory processes.

T<sub>Regs</sub> exhibit a plethora of immune regulating functions that have been mostly studied in terms of their impact on T-cell-responses. However, most components of the innate and adaptive immunity appear to be affected directly or indirectly by T<sub>Regs</sub>. Taken

together, T<sub>Regs</sub> keep the immune system in balance. Consequently, reduced or deficient T<sub>Regs</sub> are associated with autoimmunity and an increased risk for developing aGVHD after alloHSCT. During the last five years, adoptive T<sub>Reg</sub> transfer and (pharmacological) means (e.g. low-dose IL-2) for promoting an *in vivo* T<sub>Regs</sub> expansion have both been heavily investigated and emerging as a promising option for treating GVHD. However, it is important to note that increased T<sub>Reg</sub> frequencies are not *per se* beneficial. In malignancies the immune suppressive effect of T<sub>Regs</sub> is regularly “hijacked” by tumor cells, which should be always carefully considered in patients transplanted for underlying neoplasias. Compelling evidence suggests that T<sub>Reg</sub> accumulation plays a key role for the tumor immune escape – one of the hallmarks of cancer.

Taken together, T<sub>Regs</sub> are a double-edged sword that can be “boon and bane” to the host depending on the immunological situation and underlying disease(s).



## 6 AIMS

The aim of this thesis was to further decipher the impact of MSCs on the immune system. The following questions were addressed:

1. MSCs are often transfused into inflammatory environments; a potent protection from oxidative stress is necessary to maintain their immune regulatory function. HO-1 is a potent anti-oxidative, immune regulatory and cytoprotective molecule that, as previously shown, furthermore exerts a T-cell suppressive effect in rat MSCs [320]. The questions addressed in the first study were therefore: does HO-1 serve a dual role in human MSCs as an antioxidant with immune regulating functions? How is its expression and function impacted by inflammatory licensing?
2. HLH is a highly inflammatory disease of often-fatal outcome. The only curative regimen for this disease is allogeneic HSCT. There are cases in which a suitable transplant is not available or the health condition of the patient does not allow the induction of the therapy. Could MSCs therefore constitute a mean to bridge the therapeutic gap and furthermore limit the disease-associated hyper-inflammation until allogeneic HSCT is feasible? Does MSC treatment lead to a measurable immunological impact?
3. MSCs have been applied in studies to treat complications after alloHSCT and aGVHD. Do MSCs transfused in patients lead to measurable immunological alterations compared to placebo controls and for how long are these alterations present?
4. Recently, it was shown for animal models that regulation of inflammation by MSCs has been associated with the induction of immune suppressive myeloid cells [22]. Do infused MSCs lead to the induction of a regulatory phenotype in myeloid cells in patients after with aGVHD after aHSCT and do these myeloid cells hold a suppressive capacity that potentially limits GVHD?

## 7 MATERIAL AND METHODS

All information regarding material and applied methods is detailed in the respective papers (I-IV). This section addresses some general aspects.

### 7.1 PATIENTS AND DONORS

The studies included in this thesis were all approved by the ethics committees of the Karolinska University Hospital (Stockholm, Sweden) and the University Hospital of Erlangen (Erlangen, Germany) respectively. Healthy donors and patients respectively their parents signed an informed consent in accordance to the Declaration of Helsinki.

Patients were enrolled from the Hematology Center at the Karolinska University Hospital in Huddinge and the Department of Hematology and Oncology at the University Hospital of Erlangen, Germany. The patients undergoing alloHSCT were treated with standardized protocols following international guidelines and recommendations.

In the presented studies, adoptive MSC transfer was utilized for steroid refractory acute GVHD and HSCT related complications [51] and the treatment of HLH [85]. Steroid refractoriness in GVHD patients was diagnosed, if steroid treatment ( $\geq 2$  mg per kg per day) led (A) to no clinical improvement after at least seven days, or (B) in the case of GVHD progression by at least one grade, within 72h.

#### 7.1.1 Patient material

Peripheral blood mononuclear cells (PBMCs) were retrieved by density gradient-based centrifugation and stored in 10% dimethyl sulfoxide (DMSO) in liquid nitrogen until further use. For subsequent isolations of specific cell subsets such as monocytes or T-cells magnetic bead-based methods (Miltenyi Biotec, Bergisch Gladbach, Germany) were applied.

Serum was immediately processed and stored at  $-80^{\circ}\text{C}$  until analysis.

MSCs were isolated from the bone marrow of unrelated unmatched donors harvested from the iliac crest as described previously in detail [94, 321]. In short, heparinized bone marrow was separated according to the density gradient and the bone marrow mononuclear cells were plated in DMEM with 10% FCS. The culture procedure was in line with the recommendations of the MSC consortium (EBMT) and the Swedish Medical Products Agency. The purified and expanded MSCs fulfilled the ISCT criteria: they expressed CD73, CD90 and CD105 and were negative for CD3, CD14, CD31, CD34, CD45, and HLA-DR. They differentiated into cartilage, bone and fat (multipotency) using special culture conditions and inhibited mixed lymphocyte cultures *in vitro* (immune regulation). All cells for clinical and research purposes were cultured according to well-established protocols for three passages [322] and subsequently cryopreserved in 10% DMSO until infusion or further utilization. Release criteria for MSCs included viability of  $>95\%$ , absence of visible clumps, and sterility. In average two million cells per kg bodyweight (range: 1.5 – 2.2) diluted in saline solution supplemented with 10% AB plasma were infused for 15 – 20 minutes.

## 7.2 METHODS

### 7.2.1 T-cell suppression assays (Paper I and III)

Mixed lymphocyte reactions (MLRs) or bead-triggered (i.e. anti-CD3- and anti-CD28 activating beads) T-cell stimulation have been established to mimic T-cell responses *in vitro* and can be used for evaluating the suppressive activity of regulatory cells such as MSCs. Briefly, the impact of immunosuppressive cells on classical lymphocyte responses to activation such as proliferation (primarily) or cytokine production are assessed.

In this thesis two common experimental set-ups were utilized: (1) for assessing the suppressive capacity of MSCs [31], pooled irradiated (for preventing proliferation) allogeneic peripheral blood lymphocytes (PBLs) from five healthy donors were used as stimulators of non-irradiated PBLs from another donor (responder cells) and co-cultured for five days. Proliferation (measured by quantifying the <sup>3</sup>H-thymidine incorporation in T-cells) was comparatively analyzed in cultures in which MSCs were present (ratio of 1:10 to the responder PBLs) or absent. (2) The suppressive capacity of MDSCs [190] was estimated by measuring the proliferation of purified, autologous T-cells in response to anti-CD2/CD3/CD28-T-cell stimulating bead-coupled antibodies. For quantifying T-cell proliferation, T-cells were pre-labeled with carboxyfluorescein diacetate, succinimidyl ester (CFSE) before the assay. CFSE diffuses passively into cells, where it interacts with intracellular esterases and amines and becomes fluorescent. The formed dye-protein adduct is maintained in the cell during meiosis and inherited by the daughter cells. The dilution of the dye upon proliferation was assessed by fluorescence activated cell sorting.

### 7.2.2 FACS (Paper I-IV)

Fluorescence activated cell sorting (FACS) has become an essential method in immunology. It allows the detailed monitoring of many facets of the immune system. In short, cells stained with fluorescence labeled antibodies or dyes are acquired in a laminar stream of fluid. The cells pass through a laser beam that allows (utilizing different lasers, filters and detectors) the simultaneous detection of the cell volume (forwards scatter (FCS)), cell granularity (sideward scatter (SSC)) as well as by measuring the emitting signal of the excited fluorescent dye, the expression of the target of interest. Fluorescent antibodies stain antigenic surface markers. The application of different fluorochromes in combination with the data gained by FCS and SSC makes it possible to distinguish different cells subsets. Furthermore, utilizing fixation/permeabilization reagents also intracellular expressed cytokines e.g. IL-10, IL-17, IFN- $\gamma$  and transcription factors such as FOXP3 or STAT can be analyzed. Besides phenotype, FACS gives the possibility to examine the viability (7-amino-actinomycin D (7AAD)/AnnexinV), proliferation (Ki67, CFSE) and the metabolism respectively oxidation status of cells. All above described application were utilized at some point in this thesis to analyze cell population in PBMCs [31, 51, 85, 190] respectively bone marrow cells [85] isolated by gradient based centrifugation.

### 7.2.3 ELISA and multiplex (Paper II and IV)

Enzyme-linked immunosorbent assays (ELISAs) are a standard procedure to measure cytokines in serum or supernatant. The principle of the so-called sandwich ELISA is based on capture antibodies (bound to pre-coated micro plates), which bind one specific target antigen contained in the sample (in our studies IFN- $\gamma$ , IL-10 and PGE<sub>2</sub> in supernatants [31, 190]. After the binding incubation phase, unbound antigen is washed off and secondary specific antibody is added, to the wells. This secondary antibody is conjugated to an enzyme e.g. horseradish peroxidase. By adding the according substrate, the enzyme produces (depending on the amount of bound secondary antibody) a colored product. The resulting absorbance can be measured in a plate reader and the amount of target antigen quantitated employing a standard curve.

Multiplex cytokine assays on the other hand allow the simultaneous analysis of multiple cytokines even in small volumes. This method was used to analyze serum samples of alloH SCT patients and the HLH patient [51, 85, 190]. This method utilizes microscopic small spheric, polystyrol particle (beads), which serve as binding phase similar to coated ELISA plates described above. Each assay contains a specified mix of bead populations, which are each coated with antibodies on the surface specific for one target analyte. Each bead population is again internally labeled with a defined concentration of a fluorescent dye. These different concentrations result in different emitting fluorescence upon excitation and allowing the discrimination of the population.

In short, beads are incubated with the sample to allow binding of the respective analyte. Subsequently a biotinylated detection antibody is added, followed by the incubation with a streptavidin conjugate. This conjugate is bound to a fluorescent, which allows the specific detection of the amount of binding of the analyte. The conjugate has a high specific affinity to the analyte and emits a defined signal. Integrating all this information, allows the simultaneous classification of the beads and the quantification of the analyte in the sample.

### 7.2.4 RT-PCR (Paper I, III)

Real time polymerase chain reaction (RT-PCR) often synonymously termed quantitative real time PCR (qPCR) allows the detection and quantification of genes on the messenger RNA (mRNA) level utilizing complementary DNA (cDNA) synthesized from isolated total RNA.

Cells were lysed utilizing RLT Buffer containing 0.01%  $\beta$ -Mercaptoethanol according to manufactures instruction (RNeasy Mini Kit, Qiagen Hilden). Cell lysates were stored at -80°C, if RNA isolation was not subsequently carried out. The technology of RNeasy Kits relies on (1) the lysis by denaturing guanidine thiocyanate which also inactivates RNases and (2) subsequent purification of RNA involving several centrifugation and washing steps in which RNA is bound to silica membranes. In the last step total RNA is eluted with RNase free water. The obtained total RNA was stored at -80°C or immediately used for cDNA synthesis. cDNA synthesis requires two steps: (1) single stranded RNA is transcribed by the enzyme reverse transcriptase utilizing a RNA independent DNA-Polymerase and short oligonucleotide (primer); (2) obtained cDNA is amplified by conventional PCR (reverse-transcription PCR). Yielded cDNA was stored at -20°C.

During RT-PCR the amount of cDNA is measured in „real time“ with quantification at the end of each cycle. The quantification is detected by utilizing a fluorescent dye such as SYBR Green. SYBR Green intercalates with double stranded DNA (dsDNA) and emits a signal that correlates with the amount of dsDNA that was amplified by the according primer pair for the target gene.

The gene expression can be normalized to the expression of a reference gene (house keeping gene). For all studies included in this thesis this was *β-actin*. Relative gene expression was calculated using the  $\Delta\Delta$ -C<sub>T</sub>-formula:

$$\text{relative gene expression} = 2^{(\Delta\text{CT Target gene} - \Delta\text{CT Reference gene})}$$

We used relative gene expression to monitor the impact of inflammatory licensing on the expression of immune regulating molecules such as HO-1, COX-2 and IDO in MSCs [31] and to elucidate the immunosuppressive mechanism of MDSC after alloHSCT [190].

## 8 RESULTS AND DISCUSSION

MSCs have been widely evaluated within clinical studies and their efficacy and safety, in terms of an increased risk for infectious complications and/or acute toxicity, has been well demonstrated [11, 94, 323]. Since it is yet not unequivocally clarified, which mechanistic effects take place upon an adoptive transfer of MSCs, it is a difficult task to identify biomarkers that reflect the response to and/or the efficacy of MSC treatment. To date, most studies use the clinical response as the only parameter to value the (biological) impact of MSCs [94]. This obviously represents a hurdle, which needs to be overcome in order (1) to discriminate biological from clinical responses, (2) to develop biomarkers that identify good and bad responders towards MSC treatment, and (3) to optimize our application protocols and the patients' outcome.

As yet, most of our knowledge regarding the immunological effects of MSCs is based on *in vitro* observations and pre-clinical models. This self-evidently does not necessarily reflect the situation in patients. Aim of this thesis was to address the mode of action of MSCs focusing on the modulation of the adaptive immunity. Moreover, we attempted to transfer our *in vitro* observations into the translational clinical setting: (1) to better understand the in-patient MSC effects and (2) to deduct from these observations potential immunological biomarkers, which would allow to objectively assess the biological efficacy of transferred MSCs in the future.

Briefly, in this thesis we were able to show that MSCs via T<sub>Reg</sub>-induction directly and indirectly regulate T-cell responses. In doing so MSCs display a remarkable plasticity in terms of switching between different suppressive strategies, which is governed by their environment (**Paper I**). Furthermore, we observed that MSCs promote the skewing of monocyte polarization towards a regulatory M2 phenotype. This is of great importance for the experimental MSC treatment of diseases that are actually driven by inflammatory monocytes (such as HLH) (**Paper II**). In order to translate our findings from bench to bedside, we performed comprehensive immunome analyses in patients receiving MSCs and could *de facto* detect immune responses that were MSC-associated (**Paper II, III, IV**). Taken together our data support the notion that MSCs act in a “hit and run”-fashion [103]: infused MSCs elicit an immediate response (by e.g. releasing cytokines) that initiates an immunological cascade resulting in long lasting immune regulatory effects (Figure 3), which are active even after the disappearance of transfused MSCs.

In the following sections the main results of my thesis are summarized. The information provided should help the reader to understand the scope of the performed published studies and the general implications of these findings. For more details on experimental set-up, results, and specific discussion of the findings, please refer to the appended articles.

## 8.1 T<sub>REG</sub>-INDUCTION BY MSCs - A MATTER OF PLASTICITY (PAPER I)

The MSC-triggered promotion of immunosuppressive phenotypes in various immune cells, including the induction of T<sub>Regs</sub> from conventional T-cells has been demonstrated in several (*in vitro* and animal) studies [11, 29, 324].

Our initial interest was to investigate the impact of HO-1 on the MSC-mediated control of T-cell responses. HO-1 is a stress-responsive molecule with known anti-oxidative and immune modulating properties [325]. We found HO-1 to be highly expressed in human MSCs contributing to their resilience towards oxidative stress-induced cell death. This key feature allows them to remain operational in inflamed environments similar to the also immune modulating T<sub>Regs</sub> [235]. Since there were reports on HO-1 being involved in the suppression of T-cells by rat MSCs [320], we speculated that human MSCs express also HO-1, which as a prototypical stress-responsive molecule might be up-regulated within an inflammatory environment leading to a stronger suppressive activity.

In fact, we could show that human MSCs (1) inhibit T-cell proliferation and (2) promote the induction of T<sub>Reg</sub>-(subsets) in a HO-1 dependent fashion. In contrast to our initial hypothesis, we noticed a significant reduction of the HO-1 expression when MSCs encountered an *in vitro* alloreactive, highly inflammatory environment. Counter intuitively this HO-1 down-regulation elicited by soluble factors was not accompanied by a reduced capacity for T-cell regulation. In fact, MSCs suppressed more potently T-cells and induced more T<sub>Regs</sub> albeit HO-1 levels were very low. In order to understand this phenomenon we evaluated the impact of the inflammatory milieu on other important immune modulating molecules (e.g. IDO or COX-2) [33, 70]. Inflammatory conditioning of MSCs led to a dramatic up-regulation of COX-2, which was then central for their boosted ability to promote T<sub>Reg</sub> generation. These findings are very much in line with the current dogma of MSCs being activated by inflammatory cytokines (e.g. IFN- $\gamma$  or TNF- $\alpha$ ) in a process termed as MSC-“licensing” [33, 35]. This is important for two reasons: (1) therapeutically applied MSCs will most likely encounter an inflammatory environment since nowadays inflammatory diseases represents their main indication and (2) it can be reasoned that a MSC-“licensing” prior administration could harness their therapeutic efficacy. Of course more *in vitro* and preclinical data as well as addressing regulatory issues (e.g. compliance with GMP standards) are obligatory before considering the clinical translation. In addition, we demonstrate that the same (suppressive) function within one cell type (MSCs) can be mediated by different molecules, in our case HO-1 or COX-2, depending on the current environment further highlighting the unique functional plasticity of MSCs.

## 8.2 MYELOID CELLS AS A TARGET FOR MSC-BASED THERAPY (PAPER II)

The failure to treat a disease with the means provided by conventional therapy is one of the strongest motivations to employ experimental approaches. This was the case in a young patient suffering from a rare autosomal recessive immunological disorder that is known as familial hemophagocytic lymphohistiocytosis (FHL). Defects in lymphoid as well as myeloid cells lead to hyper-inflammation, which is often triggered by normally harmless viral infections. The name FHL is derived from a characteristic bone marrow infiltration with monocytes/macrophages that phagocyte the hematopoietic cells

leading to severe cytopenias. Without immune suppressive treatment (e.g. chemotherapy and steroids) survival time is very low and the only curative treatment remains alloHSCT.

The particular patient was treated for over several months with a combination of chemotherapy, steroids, and targeted anti-inflammation (=anti-TNF- $\alpha$  antibodies) without achieving disease control and while facing severe infectious complications. An alloHSCT was at this time not foreseeable due to the lack of a matched donor and sufficient disease control. After careful consideration we decided to treat the patients with an adoptive transfer of third-party MSCs. The transferred MSCs inhibited *in vitro* pre-testing T-cell activation and more importantly promoted the differentiation of regulatory CD206<sup>+</sup>HLA-DR<sup>low</sup>IL-10 producing M2 monocytes. This observation is very important since monocytes/macrophages play a decisive role in FHL pathophysiology. In fact and in addition to their hemophagocytic activity, it is widely assumed that suppressive M2 monocytes/macrophages in FHL patient represent a reaction - in terms of an inherent feedback-mechanism – to the systemic inflammation [326, 327]. Based on these promising biological properties we infused the MSCs without any signs of toxicity. In fact, we observed a fast decline of inflammatory cytokines (e.g. IL-15, which is produced by activated phagocytes) and FHL activity markers (e.g. serum triglyceride and ferritin levels), less IFN- $\gamma$  producing T- and NK-cells, and elevated IL-10 levels. Overall, several of the anticipated beneficial effects (based on the *in vitro* tests) in terms of T-cell and monocyte/macrophage modulation were confirmed *ex vivo* further strengthening our motivation for performing similar bench to bedside approaches always on the grounds of previously well-studied basic biology. In fact, treatment with MSCs might represent an option for patients with refractory FHL at least for bridging the time to alloHSCT and for potentially reducing the need for chemotherapeutics and the accompanying severe toxicities.

### **8.3 REGULATORY CELLS AS BIOMARKERS IN MSC TREATMENT (PAPER III AND IV)**

As pointed out several times, we still lack an objective (bio-) marker for assessing the biological (in addition to the clinical) response of MSC treatment. In order to address this translational issue we performed a comprehensive analysis of the immune system of patients receiving therapeutic MSC infusions. These (screening) efforts included almost all main populations (T-cells, B-cells, NK-cells, DCs, and monocytes) and several key subsets (e.g. nT<sub>Regs</sub>, Tr1 cells, and MDSCs) of immune cells and several relevant cytokines (e.g. IL-2, IL-4, IL-10, and TNF- $\alpha$ ) that could have been affected by MSCs based on previous reports from *in vitro* and/or animal studies [11, 22, 27, 28, 46, 47, 49, 52, 54, 71, 328].

Of note, we had the opportunity to perform our experiments on unique patient material: steroid-refractory GVHD patients enrolled in a randomized double blinded study receiving either MSC or placebo infusions. To our knowledge this was the first time a randomized control study available for investigating MSC associated effects on the immune system. Blood was drawn at 7, 30, 60 and 180 days following MSC or placebo application respectively. Shortly after MSC infusion we observed a significant drop of endothelial cell death products (serum cytokeratin 18 fragments), which represent a novel activity marker for GVHD [329]. This finding was very important for us, since it




proved that MSCs lead to a measurable (at least) non-specific reduction of the ongoing inflammation. Albeit our immune screening was rather broad T-cell analysis remained our focus since (alloreactive) donor T-cells hold a key role in initiating and driving GVHD but at the same time are decisive for elimination of residual tumor cells (=GVT effect) and protection from pathogens (e.g. viral infections).

Reconstitution of T-cells in terms of numerical alterations was not affected by MSC infusion. However, we found a rather normal  $CD4^+/CD8^+$  T-cell ratio in the MSC group. The placebo group on the other hand displayed an inversed ratio, which is often seen in alloHSCT patients. This observation together with a shift of the  $T_H1/T_H2$ -balance towards  $T_H2$ -responses further strengthens the notion that MSCs might act as a “reset button” leading to restoration of immunological homeostasis. Both, impact on  $CD4^+/CD8^+$  as well as  $T_H1/T_H2$ -ratio comes as a nice validation of results from animal studies [29, 30]. The induction of  $T_{Regs}$  including their main subsets (n $T_{Regs}$ , Tr1 and Th3 cells) (**Paper I**) represents a key MSC feature for us. It would allow MSCs to prolong their suppressive action by generating another type of suppressive cells that most likely outlives the transferred cells [103] leading to some kind of “immunologic imprinting” (by MSCs). As a matter of fact, we found significant higher levels of n $T_{Regs}$  and Tr1 cells in the circulation of MSC treated patients. This observation is very much in line with findings from several *in vitro* and animal studies performed by others and us (**Paper I**).

Our data strongly indicates that the reason for the elevated  $T_{Reg}$  levels was not an increased thymic output, but rather the proliferation of already pre-existing  $T_{Regs}$  and/or their conversion from conventional T-cells respectively. In this context we found increased IL-2 levels in patients receiving MSCs, which has already been seen under *in vitro* conditions [330], but still requires a convincing mechanistic explanation. This finding is of particular importance taking into consideration that IL-2 is central for fitness and homeostatic proliferation of  $T_{Regs}$  [331]. Remarkably,  $T_{Reg}$  frequencies correlated positively with the IL-2 serum concentrations in our treated patient cohort and current trials are actually testing the use of low-dose IL-2 in GVHD patients for promoting  $T_{Regs}$ . Based on this data, one could speculate that MSCs might in the future redundantly approach approaches that exclusively aim in boosting the  $T_{Reg}$  compartment (e.g. IL-2 or adoptive  $T_{Reg}$  transfer). One outstanding commonality of all altered immune parameters was their transient nature as both, the placebo and MSC group, were almost equal six months after treatment supporting the more and more emerging concept of using sequential MSC applications.

The so-called MDSCs are thought to represent the myeloid counterpart of  $T_{Regs}$ . Our data (**Paper II**) and a recently published study [71] indicate that human MSCs when cultured together with monocytes promote a phenotype that resembles monocytic MDSCs as found accumulated in several tumor entities [187]. Of course we were interested in confirming these observations in the GVHD patients that had received MSCs (**Paper III**). Before doing so we first had to identify and characterize MDSCs in alloHSCT patient, which led to a number of interesting results (**Paper IV**). AlloHSCT patients have increased levels of monocytic  $CD14^+HLA-DR^{low/neg}$  cells that suppress activation of autologous T-cells allowing us to term them MDSCs. The MDSC frequency peaked early after transplantation and early engraftment during a period that is characterized by (1) high levels of inflammatory cytokines (=so-called “cytokine

storm”) and (2) (myeloid) growth factors as well as an (3) increased (“emergency”) myeloopoiesis. These parameters have already been shown to be involved in MDSC accumulation and we could effectively notice a significant link between IL-6 (=inflammatory cytokine) and G-CSF (=growth factor) with MDSC frequency. The MDSCs’ T-cell suppressive activity was mediated by IDO, which appears to be also systemically activated in alloHSCT patients [261]. An inhibition of IDO led *in vitro* to a partial restoration of T-cell function, which was corroborated by the *ex vivo* data that MDSC numbers were negatively associated with T-cells’ proliferative capacity, CD3 $\zeta$  chain levels, and the expression of activation markers. Interestingly and despite their obvious T-cell suppressive function MDSCs were more abundant in more severe inflammatory GVHD, which is in line with a generalized activation of tryptophan metabolism during GVHD [332]. This finding could be indicative of a compensatory increase in regulatory MDSCs that however fail to control the overwhelming immune response that underpins GVHD.



**Figure 13: Accumulation of MDSCs in alloHSCT.** Preparatory (radio-) chemotherapy (conditioning regimen) for alloHSCT leads to tissue damage and subsequent inflammation. In addition, alloreactive donor T-cells, which are fundamental for establishing the GVT effect regularly target healthy tissue (preferably the liver, skin, and gut) of the host, resulting in a highly inflammatory condition known as GVHD. The high levels of pro-inflammatory cytokines released in this setting stimulate MDSCs as part of a physiological mechanism for the control of inflammatory damage. This stimulation most likely represents a multistep process, including an increased mobilization of myeloid progenitors from the bone marrow, a differentiation arrest and the re-programming of mature myeloid cells mediate immunosuppressive functions. Accumulating monocytic MDSCs following alloHSCT express the enzyme IDO, which exerts suppressive effects on T-cells by depleting tryptophan and via its metabolites (e.g. kynurenine). Such immunosuppressive effects include the inhibition of T-cell proliferation and IFN- $\gamma$  production as well as the downregulation of CD3 $\zeta$  [333].

Based on these results it can be speculated whether MDSC-based therapeutic approaches might represent an additional option for treating GVHD. Nevertheless, studies evaluating larger patient cohorts for longer observational periods are required to elucidate the actual potential of MDSCs in alloHSCT patients. First, we need to unequivocally clarify the impact of MDSCs on the risk of disease relapse (=GVT effect). Second, we have to assess whether MDSCs are linked to viral infection and/or reactivation, since an increasing number of publications suggests that viruses (e.g., hepatitis C virus) utilize MDSCs for escaping immunosurveillance. However, when returning back to our initial question regarding the impact of MSC infusion on the patients' MDSC we did not detect any interconnection, which might be due to the strong MDSC-promoting inflammatory signals that overshadow the effects of MSCs.

## 9 CONCLUSIONS

Nowadays, cellular therapy has emerged as a promising tool for boosting immune responses (e.g. T-cell transfer in cancer) or restoring immunological homeostasis (e.g. T<sub>Reg</sub> transfer in aGVHD). However, transferring living cells into patients naturally implies the risk for substantial, often unforeseen obstacles and consequences. A prerequisite for a successful cellular therapy is a thorough understanding of the involved immunological processes. Compared to HSCT, adoptive immunotherapy of MSCs is still in its infancy and its potential has certainly not been fully exploited. In the future, it will be an important task to elucidate the mode of action of MSCs in detail to ascertain the best way to employ them.

In this thesis the following aspects of MSC biology and function were observed:

MSCs possess potent antioxidative protective mechanisms and are not hampered by being cultured in an inflammatory milieu with abundant reactive oxygen species.

MSCs utilize the antioxidative, cytoprotective enzyme HO-1 to induce T<sub>Regs</sub> *in vitro*. This function is even potentiated upon so-called “inflammatory licensing”. MSCs display a remarkable functional plasticity and while HO-1 loses its role during the licensing process, other molecules such as COX-2 take over its T<sub>Reg</sub>-inducing capacity

MSCs transferred in a patient suffering from HLH exhibited an immune regulating potential. The infusion of MSCs led to a fast reduction of inflammatory cytokines and reduced activation of T- and NK-cells. This was accompanied by a higher prevalence of myeloid cells with an immune regulatory phenotype and an increased release of IL-10.

Upon infusion into patients suffering from steroid-refractory aGVHD, we found that patients that had received MSCs exhibited higher levels of regulatory T-cells which correlated with increased IL-2 levels. The ratio of Th1/Th2-T-cell responses appeared more balanced and lower frequencies of Th17-cells were prevalent. The observed effect was transient as MSC treated patients exhibited similar levels after 6 months as placebo treated controls. MSCs did not negatively impact the immune reconstitution.

When evaluating the myeloid compartment of patients that underwent alloHSCT we found regardless of MSCs a higher frequency of CD14<sup>+</sup>HLA-DR<sup>low/neg</sup> cells. These cells correlated with time point after transplant as well as grade of aGVHD. Elevated frequencies correlated with reduced T-cell activation as well as reduced CD3ζ chain expression. These CD14<sup>+</sup>HLA-DR<sup>low/neg</sup> cells suppressed T-cells *in vitro* utilizing IDO. Inhibition of IDO restored T-cell function and lead to upregulation of CD3ζ chain expression.

## 10 ACKNOWLEDGEMENTS

First of all, I would like to express my gratitude to all patients and donors that have agreed to participate in research studies. Without their generosity and trust in science all of these studies would not have been carried out.

I would like to thank the Karolinska Institutet, the department and the division that have made this work possible.

I would like to express my heartfelt gratitude to my supervisor **Katarina Le Blanc**: I am so thankful that you allowed me to join your group and gave me the grand possibility to work in science. You have always supported me on my journey of scientific progress and as a person. Tack så mycket!

I would like to thank all the past and present members of the Le Blanc research group: **Cecilia, Ellen, Jessica, Lindsay, Caroline, Lena, Maritha, Carolina, Kristina and Guido**, thank you all for your support, the fruitful discussions and the fun at coffee break. Thank you **Lena** and **Berit** for introducing me to the world of MSC culture, your kindness and support. A special thanks goes to **Lili**. You have helped me so many times with various administrative challenges. Tusen tack without you I would have been lost.

Ευχαριστώ πολύ, **Dimitrios Mougiakakos**. You have always inspired me with your enthusiasm for science. You taught me to never give up and always aim for higher. Thanks to all the members of the Mougiakakos research group: **Jana, Domenica, Martina, Juliane** and **Andi**, it has been so much fun working with you.

Thank you **Gunnar Nilsson** for accepting to be my co-supervisor and your support.

**Rolf Kiessling**, thank you so much for your kind support from the first minute. Thanks to all the past and present members of the Kiessling Group for the fun time.

**Andreas Mackensen** and the department of Hematology and Oncology in Erlangen thank you for the great collaboration.

All my **co-authors** and **collaborators**: thank you for your contributions that made these studies possible! The **nurses and doctors** from the hematology outpatient unit: thank you so much for your time and effort.

I would to thank all the people at **HERM** for the wonderful atmosphere and the scientific discussions.

Last but not least, I want to thank my parents, **Heidi** and **Hartmut**, my brothers and sisters and my godmother **Hansi**. You have always been there for me and encouraged me to fulfill my dream and move to Sweden. Ich danke euch von ganzem Herzen, was wäre ich ohne euch!

# 11 REFERENCES

1. Lederberg J, M.A., 'Ome Sweet 'Omics—a genealogical treasury of words. . Scientist. 2001, 2001. **15**:8.
2. Friedenstein, A.J., et al., *Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues*. Transplantation, 1968. **6**(2): p. 230-47.
3. Friedenstein, A.J., R.K. Chailakhjan, and K.S. Lalykina, *The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells*. Cell Tissue Kinet, 1970. **3**(4): p. 393-403.
4. Pittenger, M.F., et al., *Multilineage potential of adult human mesenchymal stem cells*. Science, 1999. **284**(5411): p. 143-7.
5. Owen, M. and A.J. Friedenstein, *Stromal stem cells: marrow-derived osteogenic precursors*. Ciba Found Symp, 1988. **136**: p. 42-60.
6. Caplan, A.I., *The mesengenic process*. Clin Plast Surg, 1994. **21**(3): p. 429-35.
7. Erices, A., P. Conget, and J.J. Minguell, *Mesenchymal progenitor cells in human umbilical cord blood*. Br J Haematol, 2000. **109**(1): p. 235-42.
8. Zuk, P.A., et al., *Human adipose tissue is a source of multipotent stem cells*. Mol Biol Cell, 2002. **13**(12): p. 4279-95.
9. Dominici, M., et al., *Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement*. Cytotherapy, 2006. **8**(4): p. 315-7.
10. Caplan, A.I., *Mesenchymal stem cells*. J Orthop Res, 1991. **9**(5): p. 641-50.
11. Le Blanc, K. and D. Mougiakakos, *Multipotent mesenchymal stromal cells and the innate immune system*. Nat Rev Immunol, 2012. **12**(5): p. 383-96.
12. Tolar, J., et al., *Concise review: hitting the right spot with mesenchymal stromal cells*. Stem Cells, 2010. **28**(8): p. 1446-55.
13. Bernardo, M.E., et al., *Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms*. Cancer Res, 2007. **67**(19): p. 9142-9.
14. Digirolamo, C.M., et al., *Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate*. Br J Haematol, 1999. **107**(2): p. 275-81.
15. Bork, S., et al., *DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells*. Aging Cell, 2010. **9**(1): p. 54-63.
16. Rasmusson, I., et al., *Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells*. Transplantation, 2003. **76**(8): p. 1208-13.
17. Le Blanc, K., et al., *HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells*. Exp Hematol, 2003. **31**(10): p. 890-6.
18. Le Blanc, K., *Immunomodulatory effects of fetal and adult mesenchymal stem cells*. Cytotherapy, 2003. **5**(6): p. 485-9.
19. Koc, O.N., et al., *Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)*. Bone Marrow Transplant, 2002. **30**(4): p. 215-22.
20. Schraufstatter, I.U., et al., *C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation*. J Immunol, 2009. **182**(6): p. 3827-36.
21. Moll, G., et al., *Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses*. PLoS One, 2011. **6**(7): p. e21703.
22. Nemeth, K., et al., *Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production*. Nat Med, 2009. **15**(1): p. 42-9.

23. Chen, L., et al., *Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells*. Stem Cells Dev, 2007. **16**(5): p. 719-31.
24. Aggarwal, S. and M.F. Pittenger, *Human mesenchymal stem cells modulate allogeneic immune cell responses*. Blood, 2005. **105**(4): p. 1815-22.
25. Hall, S.R., et al., *Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils*. Stem Cells, 2013. **31**(2): p. 397-407.
26. Brown, J.M., et al., *Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism*. Clin Exp Allergy, 2011. **41**(4): p. 526-34.
27. Spaggiari, G.M., et al., *Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2*. Blood, 2008. **111**(3): p. 1327-33.
28. Spaggiari, G.M., et al., *Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation*. Blood, 2006. **107**(4): p. 1484-90.
29. Uccelli, A., L. Moretta, and V. Pistoia, *Mesenchymal stem cells in health and disease*. Nat Rev Immunol, 2008. **8**(9): p. 726-36.
30. Ezquer, F., et al., *The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment*. Stem Cells, 2012. **30**(8): p. 1664-74.
31. Mougiakakos, D., et al., *The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells*. Blood, 2011. **117**(18): p. 4826-35.
32. Corcione, A., et al., *Human mesenchymal stem cells modulate B-cell functions*. Blood, 2006. **107**(1): p. 367-72.
33. Krampera, M., et al., *Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal*. Cytotherapy, 2013.
34. Ren, G., et al., *Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression*. Stem Cells, 2009. **27**(8): p. 1954-62.
35. Krampera, M., *Mesenchymal stromal cell 'licensing': a multistep process*. Leukemia, 2011. **25**(9): p. 1408-14.
36. Krampera, M., *Mesenchymal stromal cells: more than inhibitory cells*. Leukemia, 2011. **25**(4): p. 565-6.
37. Krampera, M., et al., *Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide*. Blood, 2003. **101**(9): p. 3722-9.
38. Yang, S.H., et al., *Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10*. Exp Mol Med, 2009. **41**(5): p. 315-24.
39. Augello, A., et al., *Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway*. Eur J Immunol, 2005. **35**(5): p. 1482-90.
40. Di Nicola, M., et al., *Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli*. Blood, 2002. **99**(10): p. 3838-43.
41. Bartholomew, A., et al., *Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo*. Exp Hematol, 2002. **30**(1): p. 42-8.
42. Plumas, J., et al., *Mesenchymal stem cells induce apoptosis of activated T cells*. Leukemia, 2005. **19**(9): p. 1597-604.
43. Zappia, E., et al., *Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy*. Blood, 2005. **106**(5): p. 1755-61.
44. Ramasamy, R., et al., *Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle*. Transplantation, 2007. **83**(1): p. 71-6.
45. Beyth, S., et al., *Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness*. Blood, 2005. **105**(5): p. 2214-9.

46. Spaggiari, G.M. and L. Moretta, *Interactions Between Mesenchymal Stem Cells and Dendritic Cells*. Adv Biochem Eng Biotechnol, 2012.
47. Maccario, R., et al., *Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype*. Haematologica, 2005. **90**(4): p. 516-25.
48. Ghannam, S., et al., *Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype*. J Immunol, 2010. **185**(1): p. 302-12.
49. Luz-Crawford, P., et al., *Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway*. PLoS One, 2012. **7**(9): p. e45272.
50. Selmani, Z., et al., *Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells*. Stem Cells, 2008. **26**(1): p. 212-22.
51. Jitschin, R., et al., *Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation*. Stem Cells, 2013.
52. Asari, S., et al., *Mesenchymal stem cells suppress B-cell terminal differentiation*. Exp Hematol, 2009. **37**(5): p. 604-15.
53. Traggiai, E., et al., *Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients*. Stem Cells, 2008. **26**(2): p. 562-9.
54. Rasmusson, I., et al., *Mesenchymal stem cells stimulate antibody secretion in human B cells*. Scand J Immunol, 2007. **65**(4): p. 336-43.
55. Comoli, P., et al., *Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation*. Nephrol Dial Transplant, 2008. **23**(4): p. 1196-202.
56. Poggi, A., et al., *Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors*. J Immunol, 2005. **175**(10): p. 6352-60.
57. Sotiropoulou, P.A., et al., *Interactions between human mesenchymal stem cells and natural killer cells*. Stem Cells, 2006. **24**(1): p. 74-85.
58. Crop, M.J., et al., *Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells*. Cell Transplant, 2011. **20**(10): p. 1547-59.
59. Gotherstrom, C., et al., *Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways*. Cytotherapy, 2011. **13**(3): p. 269-78.
60. DelaRosa, O., et al., *Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis*. Stem Cells Dev, 2012. **21**(8): p. 1333-43.
61. Rasmusson, I., et al., *Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes*. J Leukoc Biol, 2007. **82**(4): p. 887-93.
62. Murphy, K., et al., *Janeway's immunobiology*. 8th ed. 2012, New York: Garland Science. xix, 868 p.
63. Karlsson, H., et al., *Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses*. Blood, 2008. **112**(3): p. 532-41.
64. Carrion, F., et al., *Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients*. Lupus, 2010. **19**(3): p. 317-22.
65. von Bahr, L., et al., *Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy*. Biol Blood Marrow Transplant, 2012. **18**(4): p. 557-64.
66. Lucchini, G., et al., *Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation*. Stem Cells Int, 2012. **2012**: p. 690236.
67. Shi, C., et al., *Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands*. Immunity, 2011. **34**(4): p. 590-601.
68. Chen, L., et al., *Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice*. PLoS One, 2009. **4**(9): p. e7119.



69. Krasnodembskaya, A., et al., *Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes*. Am J Physiol Lung Cell Mol Physiol, 2012. **302**(10): p. L1003-13.
70. Francois, M., et al., *Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation*. Mol Ther, 2012. **20**(1): p. 187-95.
71. Chen, H.W., et al., *Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines*. J Immunol, 2013. **190**(10): p. 5065-77.
72. Prockop, D.J., *Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms*. Mol Ther, 2009. **17**(6): p. 939-46.
73. Yagi, H., et al., *Mesenchymal stem cells: Mechanisms of immunomodulation and homing*. Cell Transplant, 2010. **19**(6): p. 667-79.
74. Deak, E., E. Seifried, and R. Henschler, *Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications*. Int Rev Immunol, 2010. **29**(5): p. 514-29.
75. Horwitz, E.M., et al., *Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone*. Proc Natl Acad Sci U S A, 2002. **99**(13): p. 8932-7.
76. Le Blanc, K., et al., *Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta*. Transplantation, 2005. **79**(11): p. 1607-14.
77. Shake, J.G., et al., *Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects*. Ann Thorac Surg, 2002. **73**(6): p. 1919-25; discussion 1926.
78. Schulman, I.H. and J.M. Hare, *Key developments in stem cell therapy in cardiology*. Regen Med, 2012. **7**(6 Suppl): p. 17-24.
79. Williams, A.R. and J.M. Hare, *Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease*. Circ Res, 2011. **109**(8): p. 923-40.
80. Jungebluth, P., et al., *Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study*. Lancet, 2011. **378**(9808): p. 1997-2004.
81. Qiu, Y., L.A. Marquez-Curtis, and A. Janowska-Wieczorek, *Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q*. Cytotherapy, 2012. **14**(3): p. 285-95.
82. Tyndall, A., *Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases*. Pediatr Res, 2012. **71**(4 Pt 2): p. 433-8.
83. Uccelli, A., et al., *Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis*. Mol Med, 2012. **18**: p. 794-804.
84. Mazzini, L., et al., *Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study*. Cytotherapy, 2012. **14**(1): p. 56-60.
85. Mougiakakos, D., et al., *Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells*. Stem Cells Dev, 2012. **21**(17): p. 3147-51.
86. Ciccocioppo, R., et al., *Mesenchymal stromal cell infusions as rescue therapy for corticosteroid-refractory adult autoimmune enteropathy*. Mayo Clin Proc, 2012. **87**(9): p. 909-14.
87. Schwartz, G.N., et al., *Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells*. Bone Marrow Transplant, 1998. **22**(5): p. 457-68.
88. Koc, O.N., et al., *Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy*. J Clin Oncol, 2000. **18**(2): p. 307-16.

89. Lazarus, H.M., et al., *Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients*. Biol Blood Marrow Transplant, 2005. **11**(5): p. 389-98.
90. Ball, L.M., et al., *Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation*. Blood, 2007. **110**(7): p. 2764-7.
91. Bernardo, M.E., A.M. Cometa, and F. Locatelli, *Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?* Bone Marrow Transplant, 2012. **47**(3): p. 323-9.
92. Westin, J.R., et al., *Steroid-Refractory Acute GVHD: Predictors and Outcomes*. Adv Hematol, 2011. **2011**: p. 601953.
93. Arai, S., et al., *Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment*. Biol Blood Marrow Transplant, 2002. **8**(3): p. 155-60.
94. Le Blanc, K., et al., *Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells*. Lancet, 2004. **363**(9419): p. 1439-41.
95. Galipeau, J., *The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?* Cytotherapy, 2013. **15**(1): p. 2-8.
96. Ringden, O., et al., *Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon*. Leukemia, 2007. **21**(11): p. 2271-6.
97. Lazarus, H.M., et al., *Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use*. Bone Marrow Transplant, 1995. **16**(4): p. 557-64.
98. Tarte, K., et al., *Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation*. Blood, 2010. **115**(8): p. 1549-53.
99. Togel, F., et al., *Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury*. Am J Physiol Renal Physiol, 2008. **295**(1): p. F315-21.
100. Gholamrezanezhad, A., et al., *In vivo tracking of <sup>111</sup>In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis*. Nucl Med Biol, 2011. **38**(7): p. 961-7.
101. Devine, S.M., et al., *Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates*. Blood, 2003. **101**(8): p. 2999-3001.
102. Chapel, A., et al., *Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome*. J Gene Med, 2003. **5**(12): p. 1028-38.
103. von Bahr, L., et al., *Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation*. Stem Cells, 2012. **30**(7): p. 1575-8.
104. Cilloni, D., et al., *Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation*. Blood, 2000. **96**(10): p. 3637-43.
105. Pozzi, S., et al., *Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation*. Exp Hematol, 2006. **34**(7): p. 934-42.
106. Gyurkocza, B., A. Rezvani, and R.F. Storb, *Allogeneic hematopoietic cell transplantation: the state of the art*. Expert Rev Hematol, 2010. **3**(3): p. 285-99.
107. Appelbaum, F.R., *The current status of hematopoietic cell transplantation*. Annu Rev Med, 2003. **54**: p. 491-512.
108. Lorenz, E., et al., *Modification of irradiation injury in mice and guinea pigs by bone marrow injections*. J Natl Cancer Inst, 1951. **12**(1): p. 197-201.

109. Nielsen, J.S. and K.M. McNagny, *Novel functions of the CD34 family*. J Cell Sci, 2008. **121**(Pt 22): p. 3683-92.
110. Thomas, E.D., et al., *Supralethal whole body irradiation and isologous marrow transplantation in man*. J Clin Invest, 1959. **38**: p. 1709-16.
111. Bortin, M.M., *A compendium of reported human bone marrow transplants*. Transplantation, 1970. **9**(6): p. 571-87.
112. Klein, J. and A. Sato, *The HLA system. Second of two parts*. N Engl J Med, 2000. **343**(11): p. 782-6.
113. Klein, J. and A. Sato, *The HLA system. First of two parts*. N Engl J Med, 2000. **343**(10): p. 702-9.
114. Ratanatharathorn, V., et al., *Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC)*. Bone Marrow Transplant, 1992. **9**(1): p. 49-55.
115. Ratanatharathorn, V., et al., *Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes*. Blood, 1993. **81**(8): p. 2194-9.
116. Arai, F., et al., *Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche*. Cell, 2004. **118**(2): p. 149-61.
117. Thomas, L., *On immunosurveillance in human cancer*. Yale J Biol Med, 1982. **55**(3-4): p. 329-33.
118. Burnet, M., *Cancer; a biological approach. I. The processes of control*. Br Med J, 1957. **1**(5022): p. 779-86.
119. Pasquini, M.C., et al., *2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders*. Clin Transpl, 2010: p. 87-105.
120. Horowitz, M.M., et al., *Graft-versus-leukemia reactions after bone marrow transplantation*. Blood, 1990. **75**(3): p. 555-62.
121. Barnes, D.W., et al., *Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication*. Br Med J, 1956. **2**(4993): p. 626-7.
122. Weiden, P.L., et al., *Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts*. N Engl J Med, 1979. **300**(19): p. 1068-73.
123. Ruggeri, L., et al., *Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants*. Science, 2002. **295**(5562): p. 2097-100.
124. Kolb, H.J., et al., *Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients*. Blood, 1995. **86**(5): p. 2041-50.
125. Ottinger, H.D., et al., *Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow*. Blood, 1996. **88**(7): p. 2775-9.
126. Gluckman, E., et al., *Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling*. N Engl J Med, 1989. **321**(17): p. 1174-8.
127. Han, P., et al., *Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation*. Br J Haematol, 1995. **89**(4): p. 733-40.
128. Godfrey, W.R., et al., *Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function*. Blood, 2005. **105**(2): p. 750-8.
129. Wagner, J.E., et al., *Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival*. Blood, 2002. **100**(5): p. 1611-8.
130. Fernandez, M.N., et al., *Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor*. Exp Hematol, 2003. **31**(6): p. 535-44.

131. Jaroscak, J., et al., *Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase I trial using the AastromReplicell System*. Blood, 2003. **101**(12): p. 5061-7.
132. Storb, R., *Reduced-intensity conditioning transplantation in myeloid malignancies*. Curr Opin Oncol, 2009. **21 Suppl 1**: p. S3-5.
133. Levine, J.E., et al., *Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy*. Biol Blood Marrow Transplant, 2003. **9**(3): p. 189-97.
134. Mackall, C.L., *T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review*. Stem Cells, 2000. **18**(1): p. 10-8.
135. Mackall, C., et al., *Background to hematopoietic cell transplantation, including post transplant immune recovery*. Bone Marrow Transplant, 2009. **44**(8): p. 457-62.
136. Holler, E., et al., *Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation*. Blood, 2004. **104**(3): p. 889-94.
137. Petersen, S.L., et al., *A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors*. Bone Marrow Transplant, 2003. **32**(1): p. 65-72.
138. Storek, J., et al., *Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation*. Blood, 2001. **97**(11): p. 3380-9.
139. Storek, J., et al., *Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation*. Blood, 2001. **98**(2): p. 489-91.
140. Nakata, K., et al., *Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation*. Blood, 1999. **93**(2): p. 667-73.
141. Zimmerli, W., et al., *Neutrophil function and pyogenic infections in bone marrow transplant recipients*. Blood, 1991. **77**(2): p. 393-9.
142. Dulphy, N., et al., *An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation*. J Immunol, 2008. **181**(3): p. 2227-37.
143. Fagnoni, F.F., et al., *T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence*. Immunology, 2002. **106**(1): p. 27-37.
144. Heitger, A., et al., *Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation*. Blood, 1997. **90**(2): p. 850-7.
145. Fujimaki, K., et al., *Immune reconstitution assessed during five years after allogeneic bone marrow transplantation*. Bone Marrow Transplant, 2001. **27**(12): p. 1275-81.
146. Atkinson, K., et al., *T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets*. Blood, 1982. **59**(6): p. 1292-8.
147. Roux, E., et al., *Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity*. Blood, 2000. **96**(6): p. 2299-303.
148. Cose, S., *T-cell migration: a naive paradigm?* Immunology, 2007. **120**(1): p. 1-7.
149. Hakim, F.T., et al., *Age-dependent incidence, time course, and consequences of thymic renewal in adults*. J Clin Invest, 2005. **115**(4): p. 930-9.
150. Sfrikakis, P.P., et al., *Age-related thymic activity in adults following chemotherapy-induced lymphopenia*. Eur J Clin Invest, 2005. **35**(6): p. 380-7.
151. Storek, J., et al., *Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts*. Am J Hematol, 1997. **54**(2): p. 131-8.
152. Douek, D.C., et al., *Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution*. Lancet, 2000. **355**(9218): p. 1875-81.

153. Storek, J., *B-cell immunity after allogeneic hematopoietic cell transplantation*. Cytotherapy, 2002. **4**(5): p. 423-4.
154. Li, F., et al., *Impaired regeneration of the peripheral B cell repertoire from bone marrow following lymphopenia in old mice*. Eur J Immunol, 2001. **31**(2): p. 500-5.
155. Meropol, N.J., et al., *Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant*. J Clin Oncol, 2003. **21**(8): p. 1452-8.
156. Alpdogan, O., et al., *Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration*. Blood, 2006. **107**(6): p. 2453-60.
157. Bunte, M.C., et al., *Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction*. Bone Marrow Transplant, 2008. **41**(8): p. 677-86.
158. Richardson, P.G., et al., *Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease*. Ther Adv Hematol, 2012. **3**(4): p. 253-65.
159. George, J.N., et al., *Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma*. Transfusion, 2004. **44**(2): p. 294-304.
160. Cutler, C., et al., *Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation*. Biol Blood Marrow Transplant, 2005. **11**(7): p. 551-7.
161. Ho, V.T., et al., *Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation*. Biol Blood Marrow Transplant, 2005. **11**(8): p. 571-5.
162. Holler, E., et al., *Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation*. Blood, 1989. **73**(7): p. 2018-24.
163. Nguyen, T.C. and Y.Y. Han, *Plasma exchange therapy for thrombotic microangiopathies*. Organogenesis, 2011. **7**(1): p. 28-31.
164. van Esser, J.W., et al., *Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation*. Blood, 2002. **99**(12): p. 4364-9.
165. Strauss, R.G., *Therapeutic granulocyte transfusions in 1993*. Blood, 1993. **81**(7): p. 1675-8.
166. Ferrara, J.L., et al., *Graft-versus-host disease*. Lancet, 2009. **373**(9674): p. 1550-61.
167. Korngold, R. and J. Sprent, *Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow*. J Exp Med, 1978. **148**(6): p. 1687-98.
168. Holler, E., *The role of innate immunity in graft-versus-host disease and complications following allogeneic stem cell transplant*. Biol Blood Marrow Transplant, 2009. **15**(1 Suppl): p. 59-61.
169. Urbano-Ispizua, A., et al., *Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34<sup>+</sup> selected blood cells from HLA-identical siblings*. Blood, 2002. **100**(2): p. 724-7.
170. Keever-Taylor, C.A., et al., *Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion*. Biol Blood Marrow Transplant, 2001. **7**(11): p. 620-30.
171. Middleton, P.G., et al., *Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants*. Blood, 1998. **92**(10): p. 3943-8.
172. Penack, O., E. Holler, and M.R. van den Brink, *Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors*. Blood, 2010. **115**(10): p. 1865-72.
173. Ferrara, J.L., et al., *Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease*. Blood, 2011. **118**(25): p. 6702-8.

174. Levine, J.E., et al., *Low Paneth cell numbers at onset of gastrointestinal GVHD identify patients at high risk for non-relapse mortality*. Blood, 2013.
175. Ferrara, J.L.L., J.E.; Holler, E.; Edinger, M., *Recent Advances in Acute Graft-Versus-Host Disease*, in *The Hematologist* 2012.
176. Ugel, S., et al., *Therapeutic targeting of myeloid-derived suppressor cells*. Curr Opin Pharmacol, 2009. **9**(4): p. 470-81.
177. Rodriguez, P.C., et al., *Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes*. Cancer Res, 2009. **69**(4): p. 1553-60.
178. Pak, A.S., et al., *Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor*. Clin Cancer Res, 1995. **1**(1): p. 95-103.
179. Bronte, V., et al., *Tumor-induced immune dysfunctions caused by myeloid suppressor cells*. J Immunother, 2001. **24**(6): p. 431-46.
180. Gabrilovich, D.I. and S. Nagaraj, *Myeloid-derived suppressor cells as regulators of the immune system*. Nat Rev Immunol, 2009. **9**(3): p. 162-74.
181. Hoechst, B., et al., *A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells*. Gastroenterology, 2008. **135**(1): p. 234-43.
182. Ko, J.S., et al., *Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients*. Clin Cancer Res, 2009. **15**(6): p. 2148-57.
183. Poschke, I., et al., *Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign*. Cancer Res, 2010. **70**(11): p. 4335-45.
184. Yu, J., et al., *Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer*. J Immunol, 2013. **190**(7): p. 3783-97.
185. Cripps, J.G. and J.D. Gorham, *MDSC in autoimmunity*. Int Immunopharmacol, 2011. **11**(7): p. 789-93.
186. Cuenca, A.G., et al., *A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma*. Mol Med, 2011. **17**(3-4): p. 281-92.
187. Ostrand-Rosenberg, S. and P. Sinha, *Myeloid-derived suppressor cells: linking inflammation and cancer*. J Immunol, 2009. **182**(8): p. 4499-506.
188. Haile, L.A., et al., *Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway*. Gastroenterology, 2008. **135**(3): p. 871-81, 881 e1-5.
189. Highfill, S.L., et al., *Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13*. Blood, 2010. **116**(25): p. 5738-47.
190. Mougiakakos, D., et al., *Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation*. Leukemia, 2013. **27**(2): p. 377-88.
191. Wang, D., et al., *Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice*. Biol Blood Marrow Transplant, 2013. **19**(5): p. 692-702.
192. Hoechst, B., et al., *Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells*. Blood, 2011. **117**(24): p. 6532-41.
193. Almand, B., et al., *Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer*. J Immunol, 2001. **166**(1): p. 678-89.
194. Serafini, P., et al., *High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells*. Cancer Res, 2004. **64**(17): p. 6337-43.
195. Bunt, S.K., et al., *Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression*. Cancer Res, 2007. **67**(20): p. 10019-26.

196. Obermajer, N. and P. Kalinski, *Generation of myeloid-derived suppressor cells using prostaglandin E2*. Transplant Res, 2012. **1**(1): p. 15.
197. Sinha, P., et al., *Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells*. Cancer Res, 2007. **67**(9): p. 4507-13.
198. Markiewski, M.M., et al., *Modulation of the antitumor immune response by complement*. Nat Immunol, 2008. **9**(11): p. 1225-35.
199. Sinha, P., et al., *Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response*. J Immunol, 2007. **179**(2): p. 977-83.
200. Lechner, M.G., et al., *Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines*. J Transl Med, 2011. **9**: p. 90.
201. Lechner, M.G., D.J. Liebertz, and A.L. Epstein, *Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells*. J Immunol, 2010. **185**(4): p. 2273-84.
202. Bharadwaj, U., et al., *Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation*. Cancer Res, 2007. **67**(11): p. 5479-88.
203. Zhao, X., et al., *TNF signaling drives myeloid-derived suppressor cell accumulation*. J Clin Invest, 2012. **122**(11): p. 4094-104.
204. Solito, S., et al., *A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells*. Blood, 2011. **118**(8): p. 2254-65.
205. Gabrilovich, D., et al., *Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo*. Blood, 1998. **92**(11): p. 4150-66.
206. Bronte, V., et al., *Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells*. Blood, 2000. **96**(12): p. 3838-46.
207. Kusmartsev, S. and D.I. Gabrilovich, *Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species*. J Leukoc Biol, 2003. **74**(2): p. 186-96.
208. Li, Q., et al., *Role of immature myeloid Gr-1+ cells in the development of antitumor immunity*. Cancer Res, 2004. **64**(3): p. 1130-9.
209. Sinha, P., et al., *Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL*. Blood, 2011. **117**(20): p. 5381-90.
210. Thibodeau, J., et al., *Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes*. Eur J Immunol, 2008. **38**(5): p. 1225-30.
211. Kusmartsev, S., et al., *Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species*. J Immunol, 2004. **172**(2): p. 989-99.
212. Youn, J.I., et al., *Subsets of myeloid-derived suppressor cells in tumor-bearing mice*. J Immunol, 2008. **181**(8): p. 5791-802.
213. Poschke, I. and R. Kiessling, *On the armament and appearances of human myeloid-derived suppressor cells*. Clin Immunol, 2012. **144**(3): p. 250-68.
214. Gabrilovich, D.I., et al., *The terminology issue for myeloid-derived suppressor cells*. Cancer Res, 2007. **67**(1): p. 425; author reply 426.
215. Ochoa, A.C., et al., *Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma*. Clin Cancer Res, 2007. **13**(2 Pt 2): p. 721s-726s.
216. Greten, T.F., M.P. Manns, and F. Korangy, *Myeloid derived suppressor cells in human diseases*. Int Immunopharmacol, 2011. **11**(7): p. 802-7.
217. Filipazzi, P., V. Huber, and L. Rivoltini, *Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients*. Cancer Immunol Immunother, 2012. **61**(2): p. 255-63.
218. Peranzoni, E., et al., *Myeloid-derived suppressor cell heterogeneity and subset definition*. Curr Opin Immunol, 2010. **22**(2): p. 238-44.

219. Finke, J., et al., *MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy*. Int Immunopharmacol, 2011. **11**(7): p. 856-61.
220. Kusmartsev, S., et al., *Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma*. Clin Cancer Res, 2008. **14**(24): p. 8270-8.
221. Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte, *Coordinated regulation of myeloid cells by tumours*. Nat Rev Immunol, 2012. **12**(4): p. 253-68.
222. Yang, R., et al., *CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells*. Cancer Res, 2006. **66**(13): p. 6807-15.
223. Mandruzzato, S., et al., *IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients*. J Immunol, 2009. **182**(10): p. 6562-8.
224. Gallina, G., et al., *Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells*. J Clin Invest, 2006. **116**(10): p. 2777-90.
225. Serafini, P., et al., *Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells*. Cancer Res, 2008. **68**(13): p. 5439-49.
226. Dugast, A.S., et al., *Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion*. J Immunol, 2008. **180**(12): p. 7898-906.
227. Lesokhin, A.M., et al., *Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment*. Cancer Res, 2012. **72**(4): p. 876-86.
228. Kusmartsev, S., et al., *Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma*. J Immunol, 2008. **181**(1): p. 346-53.
229. Schmielau, J. and O.J. Finn, *Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients*. Cancer Res, 2001. **61**(12): p. 4756-60.
230. Brandau, S., et al., *Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties*. J Leukoc Biol, 2011. **89**(2): p. 311-7.
231. Movahedi, K., et al., *Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity*. Blood, 2008. **111**(8): p. 4233-44.
232. Haile, L.A., et al., *CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice*. J Immunol, 2010. **185**(1): p. 203-10.
233. Dolcetti, L., et al., *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF*. Eur J Immunol, 2010. **40**(1): p. 22-35.
234. Li, H., et al., *Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1*. J Immunol, 2009. **182**(1): p. 240-9.
235. Mougiakakos, D., C.C. Johansson, and R. Kiessling, *Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death*. Blood, 2009. **113**(15): p. 3542-5.
236. Nagaraj, S., et al., *Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer*. Nat Med, 2007. **13**(7): p. 828-35.
237. Talmadge, J.E., *Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy*. Clin Cancer Res, 2007. **13**(18 Pt 1): p. 5243-8.
238. Rodriguez, P.C., D.G. Quiceno, and A.C. Ochoa, *L-arginine availability regulates T-lymphocyte cell-cycle progression*. Blood, 2007. **109**(4): p. 1568-73.
239. Bronte, V. and P. Zanovello, *Regulation of immune responses by L-arginine metabolism*. Nat Rev Immunol, 2005. **5**(8): p. 641-54.



240. Morris, S.M., Jr., D. Kepka-Lenhart, and L.C. Chen, *Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells*. Am J Physiol, 1998. **275**(5 Pt 1): p. E740-7.
241. Gordon, S., *Alternative activation of macrophages*. Nat Rev Immunol, 2003. **3**(1): p. 23-35.
242. Zea, A.H., et al., *Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion*. Cancer Res, 2005. **65**(8): p. 3044-8.
243. De Santo, C., et al., *Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans*. J Clin Invest, 2008. **118**(12): p. 4036-48.
244. Bingisser, R.M., et al., *Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway*. J Immunol, 1998. **160**(12): p. 5729-34.
245. Harari, O. and J.K. Liao, *Inhibition of MHC II gene transcription by nitric oxide and antioxidants*. Curr Pharm Des, 2004. **10**(8): p. 893-8.
246. Rivoltini, L., et al., *Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction*. Immunol Rev, 2002. **188**: p. 97-113.
247. Bronte, V., et al., *IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice*. J Immunol, 2003. **170**(1): p. 270-8.
248. Kusmartsev, S. and D.I. Gabrilovich, *STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion*. J Immunol, 2005. **174**(8): p. 4880-91.
249. Nathan, C. and A. Cunningham-Bussel, *Beyond oxidative stress: an immunologist's guide to reactive oxygen species*. Nat Rev Immunol, 2013. **13**(5): p. 349-61.
250. Liou, G.Y. and P. Storz, *Reactive oxygen species in cancer*. Free Radic Res, 2010. **44**(5): p. 479-96.
251. Fisher, R.I. and F. Bostick-Bruton, *Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide*. J Immunol, 1982. **129**(4): p. 1770-4.
252. Corzo, C.A., et al., *Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells*. J Immunol, 2009. **182**(9): p. 5693-701.
253. Hildeman, D.A., et al., *Control of Bcl-2 expression by reactive oxygen species*. Proc Natl Acad Sci U S A, 2003. **100**(25): p. 15035-40.
254. Sauer, H., M. Wartenberg, and J. Hescheler, *Reactive oxygen species as intracellular messengers during cell growth and differentiation*. Cell Physiol Biochem, 2001. **11**(4): p. 173-86.
255. Fichtner-Feigl, S., et al., *Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2*. Cancer Res, 2008. **68**(9): p. 3467-75.
256. Filipazzi, P., et al., *Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine*. J Clin Oncol, 2007. **25**(18): p. 2546-53.
257. Eruslanov, E., et al., *Aberrant PGE(2) metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells*. Int Immunopharmacol, 2011. **11**(7): p. 848-55.
258. Terabe, M., et al., *Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence*. J Exp Med, 2003. **198**(11): p. 1741-52.
259. Serafini, P., *Editorial: PGE2-producing MDSC: a role in tumor progression?* J Leukoc Biol, 2010. **88**(5): p. 827-9.
260. Mellor, A.L. and D.H. Munn, *IDO expression by dendritic cells: tolerance and tryptophan catabolism*. Nat Rev Immunol, 2004. **4**(10): p. 762-74.
261. Landfried, K., et al., *Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase*. Blood, 2011. **118**(26): p. 6971-4.

262. Taylor, M.W. and G.S. Feng, *Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism*. FASEB J, 1991. **5**(11): p. 2516-22.
263. Huang, B., et al., *Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host*. Cancer Res, 2006. **66**(2): p. 1123-31.
264. Pan, P.Y., et al., *Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer*. Cancer Res, 2010. **70**(1): p. 99-108.
265. Mougiakakos, D., et al., *Regulatory T cells in cancer*. Adv Cancer Res, 2010. **107**: p. 57-117.
266. Hanson, E.M., et al., *Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells*. J Immunol, 2009. **183**(2): p. 937-44.
267. Gershon, R.K. and K. Kondo, *Cell interactions in the induction of tolerance: the role of thymic lymphocytes*. Immunology, 1970. **18**(5): p. 723-37.
268. Sakaguchi, S., et al., *Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases*. J Immunol, 1995. **155**(3): p. 1151-64.
269. Sakaguchi, S., et al., *Regulatory T cells and immune tolerance*. Cell, 2008. **133**(5): p. 775-87.
270. Dieckmann, D., et al., *Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]*. J Exp Med, 2002. **196**(2): p. 247-53.
271. Allan, S.E., et al., *The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs*. J Clin Invest, 2005. **115**(11): p. 3276-84.
272. Sojka, D.K., et al., *IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition*. J Immunol, 2004. **172**(10): p. 6136-43.
273. Morgan, D.A., F.W. Ruscetti, and R. Gallo, *Selective in vitro growth of T lymphocytes from normal human bone marrows*. Science, 1976. **193**(4257): p. 1007-8.
274. Liao, W., J.X. Lin, and W.J. Leonard, *Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy*. Immunity, 2013. **38**(1): p. 13-25.
275. Pandiyan, P., et al., *CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells*. Nat Immunol, 2007. **8**(12): p. 1353-62.
276. Hartigan-O'Connor, D.J., et al., *Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells*. J Immunol Methods, 2007. **319**(1-2): p. 41-52.
277. Liu, W., et al., *CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells*. J Exp Med, 2006. **203**(7): p. 1701-11.
278. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky, *Foxp3 programs the development and function of CD4+CD25+ regulatory T cells*. Nat Immunol, 2003. **4**(4): p. 330-6.
279. Hori, S., T. Nomura, and S. Sakaguchi, *Control of regulatory T cell development by the transcription factor Foxp3*. Science, 2003. **299**(5609): p. 1057-61.
280. van der Vliet, H.J. and E.E. Nieuwenhuis, *IPEX as a result of mutations in FOXP3*. Clin Dev Immunol, 2007. **2007**: p. 89017.
281. Bennett, C.L., et al., *The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3*. Nat Genet, 2001. **27**(1): p. 20-1.
282. Wieczorek, G., et al., *Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue*. Cancer Res, 2009. **69**(2): p. 599-608.

283. Levings, M.K., et al., *The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells*. Int Arch Allergy Immunol, 2002. **129**(4): p. 263-76.
284. Takahashi, T., et al., *Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state*. Int Immunol, 1998. **10**(12): p. 1969-80.
285. Thornton, A.M. and E.M. Shevach, *CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production*. J Exp Med, 1998. **188**(2): p. 287-96.
286. Shevach, E.M., *CD4+ CD25+ suppressor T cells: more questions than answers*. Nat Rev Immunol, 2002. **2**(6): p. 389-400.
287. Asseman, C., et al., *An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation*. J Exp Med, 1999. **190**(7): p. 995-1004.
288. Li, M.O., Y.Y. Wan, and R.A. Flavell, *T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation*. Immunity, 2007. **26**(5): p. 579-91.
289. Roncarolo, M.G., et al., *Interleukin-10-secreting type 1 regulatory T cells in rodents and humans*. Immunol Rev, 2006. **212**: p. 28-50.
290. Chen, Y., et al., *Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis*. Science, 1994. **265**(5176): p. 1237-40.
291. Roncarolo, M.G. and M.K. Levings, *The role of different subsets of T regulatory cells in controlling autoimmunity*. Curr Opin Immunol, 2000. **12**(6): p. 676-83.
292. Baratelli, F., et al., *Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells*. J Immunol, 2005. **175**(3): p. 1483-90.
293. Mahic, M., et al., *FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism*. J Immunol, 2006. **177**(1): p. 246-54.
294. Collison, L.W., et al., *The inhibitory cytokine IL-35 contributes to regulatory T-cell function*. Nature, 2007. **450**(7169): p. 566-9.
295. Oberle, N., et al., *Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling*. J Immunol, 2007. **179**(6): p. 3578-87.
296. Miyara, M. and S. Sakaguchi, *Natural regulatory T cells: mechanisms of suppression*. Trends Mol Med, 2007. **13**(3): p. 108-16.
297. Liu, H., et al., *The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression*. Eur J Immunol, 2008. **38**(11): p. 3114-26.
298. Shalev, I., et al., *The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis*. Hepatology, 2009. **49**(2): p. 387-97.
299. Bopp, T., et al., *Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression*. J Exp Med, 2007. **204**(6): p. 1303-10.
300. Deaglio, S., et al., *Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression*. J Exp Med, 2007. **204**(6): p. 1257-65.
301. Vignali, D.A., L.W. Collison, and C.J. Workman, *How regulatory T cells work*. Nat Rev Immunol, 2008. **8**(7): p. 523-32.
302. Efimova, O., P. Szankasi, and T.W. Kelley, *Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells*. PLoS One, 2011. **6**(1): p. e16013.
303. Zhao, D.M., et al., *Activated CD4+CD25+ T cells selectively kill B lymphocytes*. Blood, 2006. **107**(10): p. 3925-32.
304. Cao, X., et al., *Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance*. Immunity, 2007. **27**(4): p. 635-46.

305. Hoffmann, P., et al., *Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation*. J Exp Med, 2002. **196**(3): p. 389-99.
306. Taylor, P.A., C.J. Lees, and B.R. Blazar, *The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality*. Blood, 2002. **99**(10): p. 3493-9.
307. Bacchetta, R., et al., *High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells*. J Exp Med, 1994. **179**(2): p. 493-502.
308. Mielke, S., et al., *Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease*. Blood, 2007. **110**(5): p. 1689-97.
309. Magenau, J.M., et al., *Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease*. Biol Blood Marrow Transplant, 2010. **16**(7): p. 907-14.
310. Weston, L.E., A.F. Geczy, and H. Briscoe, *Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD*. Bone Marrow Transplant, 2006. **37**(2): p. 207-12.
311. Edinger, M., et al., *CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation*. Nat Med, 2003. **9**(9): p. 1144-50.
312. Ermann, J., et al., *Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD*. Blood, 2005. **105**(5): p. 2220-6.
313. Nguyen, V.H., et al., *The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation*. Blood, 2008. **111**(2): p. 945-53.
314. Brunstein, C.G., et al., *Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics*. Blood, 2011. **117**(3): p. 1061-70.
315. Di Ianni, M., et al., *Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation*. Blood, 2011. **117**(14): p. 3921-8.
316. Di Ianni, M., et al., *Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation*. Best Pract Res Clin Haematol, 2011. **24**(3): p. 459-66.
317. Ukena, S.N., et al., *Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells*. Ann Hematol, 2011. **90**(2): p. 213-8.
318. Trzonkowski, P., et al., *First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells*. Clin Immunol, 2009. **133**(1): p. 22-6.
319. Koreth, J., et al., *Interleukin-2 and regulatory T cells in graft-versus-host disease*. N Engl J Med, 2011. **365**(22): p. 2055-66.
320. Chabannes, D., et al., *A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells*. Blood, 2007. **110**(10): p. 3691-4.
321. Le Blanc, K., et al., *Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study*. Lancet, 2008. **371**(9624): p. 1579-86.
322. Le Blanc, K., et al., *Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells*. Leukemia, 2007. **21**(8): p. 1733-8.
323. Auletta, J.J., R.J. Deans, and A.M. Bartholomew, *Emerging roles for multipotent, bone marrow-derived stromal cells in host defense*. Blood, 2012. **119**(8): p. 1801-9.
324. Burr, S.P., F. Dazzi, and O.A. Garden, *Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?* Immunol Cell Biol, 2013. **91**(1): p. 12-8.
325. Simon, T., I. Anegón, and P. Blancou, *Heme oxygenase and carbon monoxide as an immunotherapeutic approach in transplantation and cancer*. Immunotherapy, 2011. **3**(4 Suppl): p. 15-8.
326. Henter, J.I., et al., *Hypercytokinemia in familial hemophagocytic lymphohistiocytosis*. Blood, 1991. **78**(11): p. 2918-22.

327. Gordon, S. and P.R. Taylor, *Monocyte and macrophage heterogeneity*. Nat Rev Immunol, 2005. **5**(12): p. 953-64.
328. Meisel, R., et al., *Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation*. Blood, 2004. **103**(12): p. 4619-21.
329. Luft, T., et al., *Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease*. Blood, 2007. **110**(13): p. 4535-42.
330. Rasmusson, I., et al., *Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms*. Exp Cell Res, 2005. **305**(1): p. 33-41.
331. Maloy, K.J. and F. Powrie, *Fueling regulation: IL-2 keeps CD4<sup>+</sup> Treg cells fit*. Nat Immunol, 2005. **6**(11): p. 1071-2.
332. Jaspersen, L.K., et al., *Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality*. Blood, 2009. **114**(24): p. 5062-70.
333. Le Blanc, K.J., R.; Mougiakakos, D., *Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: A double-edged sword?* Oncoimmunology, 2013. **2**(7).